

Table I-4  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
 By Primary Cancer Site, Sex and Time Period

All Races

Site	Incidence <sup>a</sup> (2000-2004)			US Mortality <sup>b</sup> (2000-2004)			Survival <sup>c</sup> (1996-2003)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	470.1	555.8	411.3	192.7	238.7	162.2	64.9	64.6	65.2
Oral Cavity & Pharynx:	10.5	15.6	6.1	2.7	4.1	1.5	59.1	57.6	62.6
Lip	0.9	1.5	0.4	0.0	0.0	0.0	89.9	90.3	87.6
Tongue	2.7	4.1	1.6	0.6	0.9	0.4	56.9	56.2	58.1
Salivary gland	1.2	1.6	0.9	0.2	0.4	0.2	74.3	69.1	80.7
Floor of mouth	0.7	1.0	0.4	0.0	0.1	0.0	51.8	49.0	57.8
Gum & other oral cavity	1.6	1.9	1.3	0.4	0.5	0.3	59.1	54.9	63.9
Nasopharynx	0.7	1.0	0.4	0.2	0.3	0.1	58.5	57.2	61.5
Tonsil	1.5	2.5	0.6	0.2	0.3	0.1	61.0	61.9	57.4
Oropharynx	0.3	0.5	0.2	0.2	0.3	0.1	36.9	35.6	40.0
Hypopharynx	0.7	1.3	0.3	0.1	0.2	0.0	29.6	29.3	30.3
Other oral cavity & pharynx	0.2	0.4	0.1	0.6	0.9	0.3	30.8	29.6	33.2
Digestive System:	89.5	109.9	73.5	45.9	58.8	36.0	44.6	42.6	46.8
Esophagus	4.6	7.9	2.0	4.4	7.8	1.8	15.6	15.3	16.8
Stomach	8.1	11.4	5.6	4.2	5.9	3.0	24.3	22.6	26.9
Small intestine	1.8	2.2	1.5	0.4	0.5	0.3	56.6	55.4	57.8
Colon & Rectum:	51.6	60.8	44.6	19.4	23.5	16.4	64.0	64.0	64.0
Colon	37.4	42.5	33.5	-	-	-	63.5	64.0	63.1
Rectum	14.3	18.3	11.1	-	-	-	65.0	64.1	66.2
Anus, anal canal & anorectum	1.5	1.3	1.6	0.2	0.2	0.2	67.1	60.2	72.1
Liver & Intrahep:	6.2	9.5	3.4	4.9	7.1	3.1	10.8	10.4	11.7
Liver	5.6	8.8	2.9	3.8	5.9	2.1	11.4	10.7	13.0
Intrahep bile duct	0.6	0.7	0.5	1.1	1.2	0.9	6.0	6.4	5.5
Gallbladder	1.2	0.8	1.5	0.7	0.5	0.8	15.1	14.0	15.5
Other biliary	1.7	2.1	1.4	0.5	0.6	0.5	18.6	19.5	17.7
Pancreas	11.4	12.9	10.1	10.6	12.2	9.2	5.0	4.9	5.1
Retroperitoneum	0.4	0.4	0.4	0.1	0.1	0.1	51.9	49.5	54.3
Peritoneum, omentum & mesentery	0.6	0.1	1.1	0.2	0.1	0.4	30.2	42.7	29.3
Other digestive system	0.5	0.5	0.4	0.3	0.4	0.3	8.0	6.4	9.4
Respiratory System:	69.1	89.0	54.3	56.3	76.3	41.8	18.5	18.0	19.1
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.2	0.2	0.1	54.4	52.0	57.8
Larynx	3.7	6.6	1.4	1.3	2.4	0.5	62.9	64.1	58.3
Lung & bronchus	64.5	81.2	52.3	54.7	73.4	41.1	15.0	13.0	17.4
Pleura <sup>d</sup>	0.0	0.1	0.0	0.1	0.2	0.0	27.8	28.4	17.7
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	46.4	45.5	47.3
Bones & joints	0.9	1.0	0.8	0.4	0.5	0.3	67.9	64.4	72.4
Soft tissue (incl heart)	3.1	3.7	2.6	1.3	1.4	1.1	66.3	66.6	66.0
Skin (ex basal & squam):	20.3	26.0	16.3	3.5	5.3	2.2	90.8	88.8	93.3
Melanoma of the skin	18.5	23.6	14.9	2.6	3.9	1.7	91.1	89.1	93.5
Other non-epithelial skin	1.8	2.4	1.3	0.8	1.4	0.4	87.8	85.1	91.0
Breast	69.6	1.1	127.8	14.5	0.3	25.5	88.6	85.0	88.6
Breast ( <i>in situ</i> )	15.7	0.1	29.4	-	-	-	100.0	100.0	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 17 areas. California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

<sup>d</sup> Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table I-4 - continued  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
 By Primary Cancer Site, Sex and Time Period

All Races

Site	Incidence <sup>a</sup> (2000-2004)			US Mortality <sup>b</sup> (2000-2004)			Survival <sup>c</sup> (1996-2003)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	26.5	-	49.1	9.3	-	16.5	69.7	-	69.7
Cervix uteri	4.5	-	8.7	1.4	-	2.6	71.6	-	71.6
Corpus uteri	12.3	-	22.7	1.1	-	2.0	83.9	-	83.9
Uterus, NOS	0.3	-	0.6	1.3	-	2.2	30.0	-	30.0
Ovary <sup>d</sup>	7.4	-	13.5	5.0	-	8.9	44.9	-	44.9
Vagina	0.4	-	0.7	0.1	-	0.2	50.3	-	50.3
Vulva	1.2	-	2.2	0.3	-	0.5	77.8	-	77.8
Other female genital system	0.4	-	0.7	0.1	-	0.2	64.4	-	64.4
Male Genital System:	77.0	174.4	-	10.7	28.3	-	98.1	98.1	-
Prostate	73.9	168.0	-	10.5	27.9	-	98.4	98.4	-
Testis	2.7	5.3	-	0.1	0.3	-	95.4	95.4	-
Penis	0.4	0.9	-	0.1	0.2	-	68.7	68.7	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	83.6	83.6	-
Urinary System:	34.8	56.4	18.7	8.7	13.9	5.2	73.5	75.0	70.2
Urinary bladder	21.1	37.3	9.4	4.3	7.5	2.3	79.5	80.9	75.3
Kidney & renal pelvis	12.8	17.8	8.8	4.2	6.1	2.8	65.5	65.1	66.3
Ureter	0.6	0.8	0.4	0.1	0.1	0.1	51.6	55.3	46.1
Other urinary system	0.3	0.5	0.1	0.1	0.1	0.1	57.5	62.9	48.6
Eye & Orbit	0.8	1.0	0.7	0.1	0.1	0.1	83.7	83.7	83.8
Brain & Nervous System: <sup>e</sup>	6.4	7.7	5.4	4.4	5.4	3.6	33.9	32.2	36.0
Brain	6.0	7.2	5.0	-	-	-	30.8	29.5	32.4
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	77.1	75.2	78.6
Endocrine System:	9.1	5.1	13.1	0.8	0.8	0.8	93.9	88.3	95.8
Thyroid	8.5	4.3	12.5	0.5	0.5	0.5	96.7	93.9	97.5
Other endocrine & thymus	0.7	0.8	0.6	0.3	0.3	0.3	60.8	61.0	60.5
Lymphoma:	22.0	26.2	18.7	8.1	10.1	6.5	66.8	64.4	69.7
Hodgkin lymphoma	2.7	3.0	2.4	0.5	0.6	0.4	84.9	83.0	87.0
Non-Hodgkin lymphoma	19.3	23.2	16.3	7.6	9.6	6.2	63.4	60.8	66.4
Myeloma	5.6	7.0	4.5	3.7	4.6	3.1	33.7	35.5	31.7
Leukemia:	12.3	16.0	9.5	7.5	10.0	5.7	49.6	49.7	49.4
Lymphocytic:	5.9	7.9	4.3	2.1	3.0	1.5	71.2	70.4	72.4
Acute lymphocytic	1.6	1.8	1.4	0.5	0.6	0.4	64.0	62.5	66.1
Chronic lymphocytic	3.9	5.5	2.8	1.5	2.2	1.0	74.2	72.8	76.4
Other lymphocytic	0.4	0.7	0.2	0.1	0.2	0.1	81.0	83.1	73.5
Myeloid & Monocytic:	5.6	7.1	4.5	3.5	4.6	2.8	29.0	28.3	29.8
Acute myeloid	3.6	4.5	3.0	2.7	3.5	2.2	21.2	20.0	22.6
Chronic myeloid	1.5	2.0	1.2	0.5	0.7	0.4	47.5	46.7	48.6
Acute monocytic	0.3	0.4	0.2	0.0	0.1	0.0	23.4	23.2	23.0
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.3	0.2	27.6	27.2	27.5
Other:	0.8	1.0	0.6	1.8	2.4	1.4	19.2	17.9	20.3
Other acute	0.3	0.4	0.3	0.8	1.1	0.6	10.3	7.4	13.0
Aleukemic, subleuk & NOS	0.4	0.6	0.3	1.0	1.3	0.8	28.9	28.8	28.6
Kaposi Sarcoma <sup>f</sup>	0.7	1.3	0.1	-	-	-	56.3	55.8	63.7
Mesothelioma <sup>f</sup>	1.1	2.1	0.4	-	-	-	8.4	6.8	13.8
Ill-defined & unspecified	10.8	12.3	9.6	14.9	18.7	12.1	15.4	18.4	12.6

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 17 areas. California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

<sup>d</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

<sup>e</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

<sup>f</sup> Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table I-5  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
 By Primary Cancer Site, Sex and Time Period

Whites

Site	Incidence <sup>a</sup> (2000-2004)			US Mortality <sup>b</sup> (2000-2004)			Survival <sup>c</sup> (1996-2003)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	477.5	556.7	423.9	190.7	234.7	161.4	65.8	65.5	66.2
Oral Cavity & Pharynx:	10.6	15.7	6.1	2.5	3.8	1.5	61.0	60.2	62.8
Lip	1.0	1.7	0.4	0.0	0.1	0.0	89.7	90.1	87.6
Tongue	2.9	4.3	1.7	0.6	0.9	0.4	59.0	58.7	59.5
Salivary gland	1.2	1.7	0.9	0.2	0.4	0.2	73.9	69.2	80.1
Floor of mouth	0.7	1.1	0.4	0.0	0.1	0.0	53.6	51.7	57.5
Gum & other oral cavity	1.6	1.9	1.3	0.4	0.5	0.3	59.9	56.7	63.5
Nasopharynx	0.4	0.6	0.2	0.2	0.2	0.1	52.9	53.0	51.9
Tonsil	1.5	2.5	0.6	0.2	0.3	0.1	64.2	65.5	58.9
Oropharynx	0.3	0.5	0.2	0.2	0.3	0.1	40.2	39.0	43.4
Hypopharynx	0.7	1.2	0.3	0.1	0.2	0.0	31.2	31.2	31.1
Other oral cavity & pharynx	0.2	0.4	0.1	0.5	0.8	0.2	34.4	33.9	35.0
Digestive System:	87.0	106.6	71.4	44.1	56.6	34.5	45.8	44.0	48.0
Esophagus	4.6	8.0	1.9	4.3	7.7	1.7	16.6	16.3	17.8
Stomach	7.1	10.2	4.7	3.7	5.2	2.6	22.3	20.6	25.1
Small intestine	1.7	2.1	1.4	0.4	0.4	0.3	57.8	56.7	59.0
Colon & Rectum:	51.2	60.4	44.0	18.9	22.9	15.9	64.9	64.9	64.9
Colon	37.0	42.2	33.0	-	-	-	64.6	64.9	64.4
Rectum	14.2	18.3	11.0	-	-	-	65.6	64.9	66.4
Anus, anal canal & anorectum	1.6	1.3	1.8	0.2	0.2	0.2	68.3	61.2	73.2
Liver & Intrahep:	5.2	7.9	2.9	4.5	6.5	2.8	10.4	9.8	11.7
Liver	4.6	7.2	2.4	3.4	5.3	1.9	11.2	10.2	13.4
Intrahep bile duct	0.6	0.7	0.5	1.1	1.2	0.9	5.9	5.9	5.6
Gallbladder	1.1	0.8	1.4	0.7	0.5	0.8	14.8	12.9	15.4
Other biliary	1.6	2.0	1.3	0.6	0.6	0.5	18.8	20.3	17.0
Pancreas	11.2	12.8	9.9	10.4	12.0	9.0	4.9	5.1	4.7
Retroperitoneum	0.4	0.5	0.4	0.1	0.1	0.1	54.1	50.9	57.3
Peritoneum, omentum & mesentery	0.7	0.1	1.2	0.2	0.1	0.4	30.0	38.5	29.4
Other digestive system	0.5	0.5	0.4	0.3	0.4	0.2	7.9	6.4	9.2
Respiratory System:	70.3	88.7	56.7	56.5	75.3	42.8	18.8	18.4	19.3
Nose, nasal cavity & middle ear	0.7	0.9	0.5	0.2	0.2	0.1	55.8	53.1	59.7
Larynx	3.7	6.5	1.4	1.2	2.2	0.5	64.4	65.4	60.7
Lung & bronchus	65.7	81.0	54.6	55.0	72.6	42.1	15.3	13.2	17.6
Pleura <sup>d</sup>	0.0	0.1	0.0	0.1	0.2	0.0	26.7	27.0	18.9
Trachea & other respiratory organs	0.2	0.3	0.1	0.1	0.1	0.1	48.0	48.6	46.0
Bones & joints	0.9	1.1	0.8	0.4	0.5	0.4	68.0	64.4	72.5
Soft tissue (incl heart)	3.1	3.7	2.6	1.3	1.5	1.1	66.8	67.4	66.0
Skin (ex basal & squam):	23.4	29.7	18.9	3.9	5.8	2.4	90.5	88.3	93.1
Melanoma of the skin	21.6	27.2	17.6	3.0	4.3	2.0	90.8	88.7	93.3
Other non-epithelial skin	1.8	2.5	1.4	0.9	1.5	0.5	86.1	83.5	89.4
Breast	71.5	1.2	132.5	14.1	0.3	25.0	89.7	86.1	89.7
Breast ( <i>in situ</i> )	16.0	0.1	30.2	-	-	-	100.0	99.7	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 17 areas. California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

<sup>d</sup> Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table I-5 - continued  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
 By Primary Cancer Site, Sex and Time Period

Whites

Site	Incidence <sup>a</sup> (2000-2004)			US Mortality <sup>b</sup> (2000-2004)			Survival <sup>c</sup> (1996-2003)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	27.2	-	50.8	9.2	-	16.3	70.7	-	70.7
Cervix uteri	4.3	-	8.5	1.2	-	2.3	72.9	-	72.9
Corpus uteri	12.8	-	23.7	1.1	-	1.9	85.6	-	85.6
Uterus, NOS	0.3	-	0.5	1.2	-	2.0	31.3	-	31.3
Ovary <sup>d</sup>	7.7	-	14.3	5.2	-	9.2	44.6	-	44.6
Vagina	0.4	-	0.7	0.1	-	0.2	52.3	-	52.3
Vulva	1.3	-	2.3	0.3	-	0.5	77.8	-	77.8
Other female genital system	0.4	-	0.7	0.1	-	0.2	63.2	-	63.2
Male Genital System:	75.3	168.8	-	9.8	26.1	-	98.6	98.6	-
Prostate	71.6	161.4	-	9.6	25.6	-	98.9	98.9	-
Testis	3.2	6.3	-	0.1	0.3	-	95.7	95.7	-
Penis	0.4	0.9	-	0.1	0.2	-	68.0	68.0	-
Other male genital system	0.1	0.3	-	0.0	0.0	-	87.3	87.3	-
Urinary System:	37.1	60.1	19.7	9.0	14.4	5.2	74.2	75.6	70.9
Urinary bladder	23.0	40.5	10.1	4.5	7.9	2.3	80.2	81.4	76.6
Kidney & renal pelvis	13.3	18.3	9.1	4.3	6.2	2.8	65.5	65.3	66.0
Ureter	0.6	0.9	0.4	0.1	0.2	0.1	53.2	57.1	47.5
Other urinary system	0.3	0.5	0.1	0.1	0.1	0.1	57.6	61.7	48.9
Eye & Orbit	0.9	1.1	0.8	0.1	0.1	0.1	83.2	83.5	82.9
Brain & Nervous System: <sup>e</sup>	7.0	8.3	5.9	4.8	5.8	3.9	33.2	31.8	35.0
Brain	6.6	7.9	5.5	-	-	-	30.1	29.0	31.6
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	78.6	78.0	78.9
Endocrine System:	9.5	5.4	13.8	0.8	0.8	0.7	94.3	89.1	96.1
Thyroid	8.9	4.6	13.2	0.5	0.5	0.5	97.0	94.3	97.8
Other endocrine & thymus	0.7	0.8	0.6	0.3	0.3	0.3	60.2	61.0	59.0
Lymphoma:	23.1	27.3	19.6	8.4	10.5	6.8	67.5	65.2	70.2
Hodgkin lymphoma	2.9	3.2	2.6	0.5	0.6	0.4	85.3	83.6	87.2
Non-Hodgkin lymphoma	20.2	24.1	17.0	7.9	9.9	6.4	64.1	61.7	66.9
Myeloma	5.2	6.6	4.1	3.5	4.4	2.8	33.4	35.3	31.2
Leukemia:	12.8	16.7	9.9	7.7	10.3	5.8	50.2	50.1	50.2
Lymphocytic:	6.3	8.4	4.6	2.2	3.1	1.6	71.9	71.1	72.9
Acute lymphocytic	1.7	1.9	1.5	0.5	0.6	0.4	64.5	63.1	66.4
Chronic lymphocytic	4.1	5.8	2.9	1.6	2.3	1.1	74.8	73.5	76.8
Other lymphocytic	0.5	0.7	0.2	0.1	0.2	0.1	81.2	83.3	73.8
Myeloid & Monocytic:	5.7	7.2	4.6	3.6	4.7	2.8	28.3	27.2	29.7
Acute myeloid	3.7	4.7	3.1	2.8	3.7	2.3	20.5	19.2	22.0
Chronic myeloid	1.5	2.0	1.2	0.5	0.6	0.4	46.8	45.1	49.3
Acute monocytic	0.3	0.4	0.3	0.0	0.1	0.0	24.3	23.0	25.3
Other myeloid & monocytic	0.2	0.2	0.1	0.2	0.3	0.2	27.9	26.4	29.5
Other:	0.8	1.0	0.6	1.9	2.5	1.4	18.5	17.3	19.4
Other acute	0.3	0.4	0.3	0.8	1.1	0.7	9.2	5.1	13.0
Aleukemic, subleuk & NOS	0.4	0.5	0.3	1.0	1.3	0.8	28.8	30.0	26.9
Kaposi Sarcoma <sup>f</sup>	0.6	1.1	0.1	-	-	-	59.2	58.1	76.8
Mesothelioma <sup>f</sup>	1.2	2.3	0.5	-	-	-	8.0	6.5	13.5
Ill-defined & unspecified	10.8	12.3	9.7	14.7	18.5	12.0	15.9	19.4	12.7

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 17 areas. California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

<sup>d</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

<sup>e</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

<sup>f</sup> Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table I-6  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
 By Primary Cancer Site, Sex and Time Period

Blacks

Site	Incidence <sup>a</sup> (2000-2004)			US Mortality <sup>b</sup> (2000-2004)			Survival <sup>c</sup> (1996-2003)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
All Sites	504.1	663.7	396.9	238.8	321.8	189.3	56.4	58.6	53.8
Oral Cavity & Pharynx:	11.1	18.1	5.7	3.9	6.8	1.7	40.1	35.5	51.3
Lip	0.1	0.2	-	-	-	-	89.9	94.8	85.0
Tongue	2.5	4.1	1.2	0.7	1.3	0.3	36.2	34.4	40.4
Salivary gland	1.0	1.2	0.9	0.2	0.2	0.1	69.5	63.5	73.7
Floor of mouth	0.9	1.5	0.4	0.1	0.1	0.0	37.9	31.8	53.3
Gum & other oral cavity	1.9	2.5	1.3	0.5	0.8	0.3	52.5	45.8	61.9
Nasopharynx	0.7	1.2	0.4	0.3	0.5	0.2	47.4	46.2	49.2
Tonsil	1.7	3.0	0.6	0.3	0.6	0.1	36.2	34.0	44.4
Oropharynx	0.6	1.1	0.3	0.4	0.7	0.2	22.7	23.2	20.0
Hypopharynx	1.3	2.4	0.4	0.2	0.4	0.1	18.8	17.9	22.6
Other oral cavity & pharynx	0.5	0.8	0.2	1.1	2.1	0.4	17.8	15.6	21.2
Digestive System:	112.2	138.7	93.4	63.8	82.9	50.7	37.3	34.7	39.8
Esophagus	6.2	10.4	3.2	6.0	10.2	3.0	10.1	9.3	11.7
Stomach	12.5	17.5	9.1	8.2	11.9	5.8	23.6	20.9	27.1
Small intestine	3.1	3.9	2.6	0.6	0.7	0.5	51.5	50.2	52.4
Colon & Rectum:	62.1	72.6	55.0	26.7	32.7	22.9	54.9	55.2	54.7
Colon	47.8	54.9	43.1	-	-	-	54.3	55.4	53.4
Rectum	14.3	17.6	11.9	-	-	-	56.6	54.5	58.7
Anus, anal canal & anorectum	1.6	1.7	1.4	0.2	0.2	0.2	60.8	53.4	68.6
Liver & Intrahep:	7.6	12.7	3.8	6.5	10.0	3.9	7.0	7.6	5.5
Liver	7.1	12.1	3.3	5.5	8.9	3.0	7.0	7.6	5.1
Intrahep bile duct	0.5	0.6	0.4	0.9	1.1	0.8	6.0	5.2	6.9
Gallbladder	1.3	0.8	1.7	0.8	0.5	1.0	12.8	20.3	10.9
Other biliary	1.5	1.9	1.2	0.4	0.5	0.4	13.3	11.4	14.5
Pancreas	15.0	16.2	13.9	13.8	15.5	12.4	4.5	3.2	5.6
Retroperitoneum	0.4	0.3	0.5	0.1	0.1	0.1	39.1	50.7	29.4
Peritoneum, omentum & mesentery	0.3	0.1	0.5	0.2	0.1	0.2	28.0	-	25.7
Other digestive system	0.6	0.6	0.6	0.4	0.6	0.4	0.0	0.0	0.0
Respiratory System:	83.5	123.4	56.3	64.8	101.3	40.8	15.7	15.1	16.5
Nose, nasal cavity & middle ear	0.6	0.9	0.4	0.2	0.3	0.1	46.5	41.2	53.5
Larynx	6.0	11.6	2.0	2.5	5.0	0.8	51.8	53.8	45.2
Lung & bronchus	76.6	110.6	53.7	62.0	95.8	39.8	12.0	10.2	14.6
Pleura <sup>d</sup>	-	-	-	0.0	0.1	0.0	-	-	-
Trachea & other respiratory organs	0.2	0.2	0.1	0.1	0.2	0.1	29.6	22.3	37.7
Bones & joints	0.7	0.8	0.7	0.5	0.6	0.4	62.6	60.3	65.1
Soft tissue (incl heart)	3.3	3.6	3.0	1.4	1.5	1.4	60.6	59.4	61.6
Skin (ex basal & squam):	2.1	2.3	1.9	1.0	1.4	0.7	86.8	83.0	90.1
Melanoma of the skin	1.0	1.1	0.9	0.4	0.5	0.4	74.4	69.9	77.4
Other non-epithelial skin	1.1	1.1	1.0	0.6	0.9	0.3	94.7	91.3	97.5
Breast	68.0	1.7	118.3	20.1	0.6	33.8	77.3	78.2	77.3
Breast ( <i>in situ</i> )	14.4	0.2	25.4	-	-	-	100.0	95.8	100.0

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 17 areas. California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

<sup>d</sup> Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table I-6 - continued  
AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES  
 By Primary Cancer Site, Sex and Time Period

Blacks

Site	Incidence <sup>a</sup> (2000-2004)			US Mortality <sup>b</sup> (2000-2004)			Survival <sup>c</sup> (1996-2003)		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
Female Genital System:	25.6	-	44.7	12.1	-	20.3	56.8	-	56.8
Cervix uteri	6.3	-	11.4	2.8	-	4.9	62.2	-	62.2
Corpus uteri	10.7	-	18.6	1.9	-	3.1	62.3	-	62.3
Uterus, NOS	0.6	-	1.0	2.4	-	4.0	25.1	-	25.1
Ovary <sup>d</sup>	5.9	-	10.1	4.5	-	7.4	38.2	-	38.2
Vagina	0.6	-	1.1	0.2	-	0.4	40.8	-	40.8
Vulva	1.1	-	1.9	0.2	-	0.3	75.1	-	75.1
Other female genital system	0.4	-	0.7	0.2	-	0.3	68.4	-	68.4
Male Genital System:	106.7	258.2	-	22.1	62.7	-	94.7	94.7	-
Prostate	105.5	255.5	-	21.9	62.3	-	94.9	94.9	-
Testis	0.7	1.4	-	0.1	0.2	-	88.2	88.2	-
Penis	0.4	1.1	-	0.1	0.2	-	69.3	69.3	-
Other male genital system	0.1	0.2	-	0.0	0.0	-	75.4	75.4	-
Urinary System:	27.6	41.6	17.9	8.0	11.6	5.8	63.5	64.3	61.5
Urinary bladder	12.6	20.3	7.6	3.7	5.3	2.8	63.9	68.2	55.5
Kidney & renal pelvis	14.3	20.4	9.7	4.1	6.1	2.8	64.2	62.0	66.3
Ureter	0.3	0.4	0.2	0.0	0.0	0.0	37.0	39.3	37.2
Other urinary system	0.4	0.5	0.4	0.2	0.2	0.2	45.5	56.2	36.4
Eye & Orbit	0.2	0.3	0.2	0.0	0.0	0.0	83.1	75.6	91.2
Brain & Nervous System: <sup>e</sup>	4.1	4.9	3.5	2.6	3.2	2.2	35.3	31.6	39.5
Brain	3.7	4.4	3.1	-	-	-	32.1	29.6	35.1
Cranial nerves & other nervous system	0.4	0.4	0.4	-	-	-	63.9	56.6	68.5
Endocrine System:	5.8	3.2	8.0	0.8	0.7	0.9	90.0	80.7	92.5
Thyroid	5.1	2.4	7.3	0.5	0.4	0.5	94.6	89.9	95.4
Other endocrine & thymus	0.7	0.8	0.6	0.3	0.3	0.3	58.6	58.7	58.1
Lymphoma:	17.0	20.9	14.0	5.6	7.0	4.6	59.7	55.4	65.1
Hodgkin lymphoma	2.4	2.8	2.1	0.4	0.5	0.3	81.5	77.0	86.6
Non-Hodgkin lymphoma	14.6	18.1	11.9	5.2	6.5	4.3	54.3	50.3	59.6
Myeloma	11.3	14.0	9.5	7.1	8.5	6.3	33.3	35.1	31.7
Leukemia:	10.2	13.2	8.1	6.7	8.8	5.3	41.1	41.2	40.8
Lymphocytic:	4.1	5.7	3.1	1.9	2.8	1.4	58.1	53.7	63.7
Acute lymphocytic	0.8	0.9	0.8	0.4	0.4	0.3	56.0	51.7	61.3
Chronic lymphocytic	3.0	4.4	2.1	1.4	2.1	1.0	58.5	52.9	65.8
Other lymphocytic	0.3	0.4	0.2	0.1	0.2	0.1	67.5	70.9	61.7
Myeloid & Monocytic:	5.0	6.3	4.1	3.0	3.7	2.5	29.5	32.5	25.7
Acute myeloid	3.2	3.9	2.7	2.2	2.7	1.9	22.6	25.2	19.1
Chronic myeloid	1.5	1.9	1.1	0.6	0.7	0.5	44.5	45.9	42.6
Acute monocytic	0.2	0.2	0.1	0.0	-	0.0	14.7	18.0	0.0
Other myeloid & monocytic	0.2	0.3	0.2	0.2	0.2	0.1	30.2	35.7	22.4
Other:	1.0	1.2	0.9	1.8	2.3	1.5	21.2	18.8	23.3
Other acute	0.4	0.5	0.3	0.6	0.9	0.5	16.1	16.5	15.3
Aleukemic, subleuk & NOS	0.6	0.7	0.5	1.2	1.5	0.9	24.7	18.8	28.8
Kaposi Sarcoma <sup>f</sup>	1.3	2.6	0.2	-	-	-	42.7	43.3	35.7
Mesothelioma <sup>f</sup>	0.6	1.1	0.2	-	-	-	15.3	9.6	27.1
Ill-defined & unspecified	12.9	15.0	11.3	18.3	24.2	14.5	9.8	10.4	9.2

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 17 areas. California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

<sup>d</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

<sup>e</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

<sup>f</sup> Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.

# SEER Incidence<sup>a</sup> and US Death Rates<sup>b</sup>, 2000-2004 5-Year Relative Survival Rates<sup>c</sup>, 1996-2003 All Cancer Combined, by Race and Sex




Figure 1-9


<sup>a</sup> Incidence rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey) and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

<sup>b</sup> Death rates are from the NCHS public use data file for the total US and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

<sup>c</sup> Survival rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Relative survival rates are expressed as percents.

Figure I-11

## 5-Year Relative Survival Rates SEER Program, 1996-2003 Both Sexes, by Race



Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

<sup>a</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.



Table II-5  
ALL CANCER SITES (Invasive)

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	39	-	-	27	-	-
1970-1973 <sup>a</sup>	-	-	-	43	-	-	31	-	-
1975-1977 <sup>b</sup>	50.1	42.3	57.1	51.0	43.3	57.8	39.8	32.7	47.2
1978-1980 <sup>b</sup>	50.4	44.0	56.4	51.4	45.3	57.1	39.6	33.3	46.5
1981-1983 <sup>b</sup>	51.6	46.1	56.7	52.8	47.6	57.6	39.6	34.2	45.6
1984-1986 <sup>b</sup>	53.5	47.7	58.9	54.7	49.1	59.9	40.7	35.5	46.4
1987-1989 <sup>b</sup>	56.4	51.6	61.0	57.7	53.3	62.1	43.6	38.8	48.9
1990-1992 <sup>b</sup>	60.9	59.5	62.3	62.4	61.3	63.5	48.2	47.3	49.2
1993-1995 <sup>b</sup>	62.2	61.1	63.4	63.4	62.4	64.4	52.8	53.5	51.9
1996-2003 <sup>b</sup>	65.9 <sup>e</sup>	65.4 <sup>e</sup>	66.3 <sup>e</sup>	67.0 <sup>e</sup>	66.6 <sup>e</sup>	67.4 <sup>e</sup>	57.0 <sup>e</sup>	59.2 <sup>e</sup>	54.5 <sup>e</sup>
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	65.5	65.5	65.5	66.3	66.2	66.4	57.4	59.8	54.7
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	77.2	71.3	81.1	79.2	73.9	82.8	62.4	54.1	67.8
45-54	70.1	63.2	75.6	71.9	65.0	77.2	57.7	54.2	61.3
55-64	67.2	66.9	67.6	68.4	67.9	69.0	58.9	62.4	53.5
65-74	63.1	66.3	58.7	63.8	66.7	59.9	56.2	63.3	45.9
75+	52.9	56.8	49.2	53.5	57.0	50.3	44.5	50.9	38.7
Under 65	70.6	66.8	74.1	72.1	68.4	75.6	59.4	58.3	60.5
65 and over	58.7	62.7	54.2	59.3	63.0	55.3	51.9	59.3	42.8

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table III-5  
BRAIN AND OTHER NERVOUS SYSTEM CANCER (Invasive)  
SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	18	16	21	19	17	21
1970-1973 <sup>a</sup>	-	-	-	20	18	22	19	19	19
1975-1977 <sup>b</sup>	23.7	22.1	25.7	23.1	21.6	25.0	26.6	20.6	35.9 <sup>f</sup>
1978-1980 <sup>b</sup>	25.0	23.9	26.5	24.5	23.5	25.8	29.1	29.5	28.4 <sup>f</sup>
1981-1983 <sup>b</sup>	25.4	24.5	26.6	24.7	24.0	25.5	32.5	33.4	30.6 <sup>f</sup>
1984-1986 <sup>b</sup>	28.7	27.6	30.1	27.9	26.7	29.4	32.6	34.3	30.4
1987-1989 <sup>b</sup>	30.7	29.1	32.6	30.1	28.2	32.4	32.5	34.1	30.4
1990-1992 <sup>b</sup>	32.2	32.8	31.5	31.3	31.7	30.7	41.4	44.0	38.2
1993-1995 <sup>b</sup>	34.0	34.6	33.1	32.8	33.2	32.3	42.1	46.3	37.4
1996-2003 <sup>b</sup>	34.5 <sup>e</sup>	32.7 <sup>e</sup>	36.9 <sup>e</sup>	33.9 <sup>e</sup>	32.4 <sup>e</sup>	35.8 <sup>e</sup>	37.3 <sup>e</sup>	33.7 <sup>e</sup>	41.6
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	34.5	32.6	36.8	34.0	32.4	36.1	34.1	30.4	38.6
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	62.8	59.7	66.8	63.5	60.8	67.1	54.0	48.0	61.5
45-54	27.4	25.0	31.0	27.4	24.6	31.7	27.7	27.6	27.6 <sup>f</sup>
55-64	12.7	10.8	15.4	12.4	10.9	14.6	11.7	-	20.9
65-74	7.1	5.2	9.2	6.8	4.9	8.9	7.6	6.0	9.2
75+	4.2	3.3	4.8	4.2	3.4	4.7	4.8	0.0	7.4
Under 65	43.7	40.6	48.0	43.4	40.5	47.5	41.2	36.2	47.3
65 and over	5.9	4.6	7.1	5.7	4.4	6.9	6.6	4.1	8.4

- <sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.
- <sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
- <sup>c</sup> Rates are based on follow-up of patients into 2004.
- <sup>d</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.
- <sup>e</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).
- <sup>f</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).
- <sup>g</sup> The standard error of the survival rate is between 5 and 10 percentage points.
- The standard error of the survival rate is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table IV-10  
FEMALE BREAST CANCER (Invasive)

## SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	63	-	-	46	-	-
1970-1973 <sup>a</sup>	-	-	-	68	-	-	51	-	-
1975-1977 <sup>b</sup>	75.1	76.7	74.6	75.9	77.9	75.2	62.3	62.6	62.2
1978-1980 <sup>b</sup>	74.9	75.6	74.7	75.6	76.2	75.4	63.8	66.9	62.0
1981-1983 <sup>b</sup>	76.7	77.5	76.5	77.7	78.7	77.4	64.1	65.2	63.4
1984-1986 <sup>b</sup>	79.3	77.9	79.8	80.4	79.7	80.6	65.1	63.8	65.8
1987-1989 <sup>b</sup>	84.2	81.5	85.2	85.3	82.8	86.1	71.2	69.5	72.1
1990-1992 <sup>b</sup>	85.5	83.4	86.3	86.7	85.1	87.3	71.7	70.0	72.8
1993-1995 <sup>b</sup>	86.6	84.3	87.5	87.9	86.3	88.5	72.8	70.0	74.6
1996-2003 <sup>b</sup>	89.2 <sup>e</sup>	87.3 <sup>e</sup>	89.9 <sup>e</sup>	90.3 <sup>e</sup>	89.0 <sup>e</sup>	90.7 <sup>e</sup>	77.9 <sup>e</sup>	76.0 <sup>e</sup>	79.1 <sup>e</sup>
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	89.1	87.3	89.8	90.2	88.6	90.7	78.3	76.8	79.2
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	253,801	63,159	190,642	211,686	48,951	162,735	22,307	7,442	14,865
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	61	54	63	62	54	64	51	46	54
Regional	31	39	28	30	39	28	37	43	33
Distant	6	5	6	6	5	6	9	9	10
Unstaged	2	2	2	2	1	2	3	2	3
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	84.9	-	-	86.6	-	-	72.5	-	-
45-54	88.9	-	-	90.1	-	-	78.4	-	-
55-64	89.8	-	-	91.0	-	-	78.6	-	-
65-74	90.4	-	-	91.1	-	-	80.1	-	-
75+	88.4	-	-	89.0	-	-	78.5	-	-
Under 65	88.3	-	-	89.7	-	-	76.6	-	-
65 and over	89.6	-	-	90.3	-	-	79.4	-	-
STAGE:									
All Stages	88.6	86.7	89.4	89.7	88.2	90.3	77.3	75.1	78.5
Localized	98.0	95.4	98.9	98.5	95.8	99.3	93.2	90.5	94.6
Regional	83.5	82.7	84.0	84.9	84.5	85.1	72.4	71.6	73.0
Distant	26.7	33.5	24.4	28.3	37.9	25.4	17.4	17.4	17.3
Unstaged	56.9	70.0	52.8	57.6	74.1	53.1	46.1	50.2	43.8
<i>IN SITU</i> <sup>h</sup>	100.0	100.0	100.0	100.0	100.0	100.0	100.0	99.2	100.0

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

<sup>h</sup> *In situ* cases are not included in the All Stages group.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table V-5  
CERVIX UTERI CANCER (Invasive)

SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	58	-	-	47	-	-
1970-1973 <sup>a</sup>	-	-	-	64	-	-	61	-	-
1975-1977 <sup>b</sup>	69.9	82.4	58.5	70.6	83.8	58.9	64.9	75.4	55.0
1978-1980 <sup>b</sup>	68.5	78.5	59.0	69.3	79.8	59.6	61.7	70.6	52.7
1981-1983 <sup>b</sup>	68.4	79.5	56.6	69.0	80.8	56.4	61.7	73.7	49.7
1984-1986 <sup>b</sup>	68.2	77.9	56.3	70.0	79.7	57.5	58.4	67.7	48.8
1987-1989 <sup>b</sup>	71.2	79.7	59.4	73.6	82.7	59.9	58.2	63.8	52.9
1990-1992 <sup>b</sup>	70.5	78.8	58.2	71.9	81.2	57.8	58.6	62.9	52.4
1993-1995 <sup>b</sup>	73.3	81.7	60.7	74.6	83.3	60.5	64.0	70.4	55.1
1996-2003 <sup>b</sup>	73.1 <sup>e</sup>	81.6	60.0	74.3 <sup>e</sup>	83.5	59.0	65.8	69.8	60.4
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	71.3	79.6	59.3	72.9	81.2	59.8	60.4	67.1	52.2
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	19,339	11,030	8,309	14,620	8,600	6,020	2,527	1,339	1,188
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	51	62	37	53	63	37	44	54	34
Regional	34	27	43	33	26	43	38	33	44
Distant	9	7	13	9	7	13	11	8	14
Unstaged	5	4	6	5	4	6	7	5	8
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	81.4	-	-	82.8	-	-	70.7	-	-
45-54	70.3	-	-	71.6	-	-	58.2	-	-
55-64	63.1	-	-	61.9	-	-	59.3	-	-
65-74	59.5	-	-	59.7	-	-	51.2	-	-
75+	42.9	-	-	41.1	-	-	46.7	-	-
Under 65	75.2	-	-	76.4	-	-	65.1	-	-
65 and over	53.0	-	-	52.6	-	-	49.7	-	-
STAGE:									
All Stages	71.6	79.5	60.1	72.9	81.0	59.9	62.2	67.6	55.0
Localized	92.0	93.6	88.0	92.8	94.5	88.3	85.7	86.6	84.0
Regional	55.7	61.4	50.6	56.4	62.9	50.1	48.2	50.6	45.8
Distant	16.5	21.6	12.7	17.5	24.4	12.0	9.2	9.3	8.9
Unstaged	60.1	72.0	47.5	59.8	70.3	47.9	56.5	65.9 <sup>f</sup>	48.6 <sup>f</sup>

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Rates are based on follow-up of patients into 2004.  
<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.  
<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).  
<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).  
<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.  
<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.  
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table VI-9  
COLON AND RECTUM CANCER (Invasive)

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	-	-	-	-	-	-
1970-1973 <sup>a</sup>	-	-	-	-	-	-	-	-	-
1975-1977 <sup>b</sup>	50.7	49.8	51.6	50.9	50.1	51.6	46.0	44.3	47.0
1978-1980 <sup>b</sup>	52.5	51.5	53.4	52.9	51.9	53.8	46.1	44.2	47.4
1981-1983 <sup>b</sup>	55.4	55.2	55.7	55.8	55.8	55.9	47.5	43.9	50.3
1984-1986 <sup>b</sup>	58.5	58.4	58.6	59.2	59.2	59.3	49.0	48.0	49.8
1987-1989 <sup>b</sup>	60.6	60.9	60.4	61.1	61.6	60.6	53.3	51.0	55.3
1990-1992 <sup>b</sup>	62.4	62.3	62.4	63.1	63.1	63.2	53.8	55.4	52.3
1993-1995 <sup>b</sup>	60.9	60.4	61.4	61.5	60.9	62.0	52.9	51.6	54.0
1996-2003 <sup>b</sup>	64.9 <sup>e</sup>	64.8 <sup>e</sup>	64.9 <sup>e</sup>	65.9 <sup>e</sup>	65.7 <sup>e</sup>	66.0 <sup>e</sup>	55.7 <sup>e</sup>	56.4 <sup>e</sup>	55.1 <sup>e</sup>
<b>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	64.4	64.8	64.1	65.5	65.9	65.1	55.7	56.1	55.4
<b>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></b>									
All Stages									
Number of cases	175,562	88,507	87,055	143,224	72,539	70,685	17,407	8,036	9,371
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	39	40	39	40	41	39	35	36	35
Regional	36	36	37	37	36	37	35	34	35
Distant	19	19	19	19	19	18	24	25	23
Unstaged	5	4	5	5	4	5	6	6	6
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></b>									
AGE AT DIAGNOSIS:									
<45	65.3	65.2	65.6	67.5	66.5	68.7	56.7	59.5	54.1
45-54	67.1	66.2	68.1	68.0	66.9	69.4	59.7	59.3	60.2
55-64	66.3	65.9	66.8	67.4	67.0	68.0	56.5	55.5	57.6
65-74	65.7	64.9	66.6	66.4	65.4	67.6	57.0	57.6	56.6
75+	59.3	59.7	59.0	60.5	61.2	60.0	45.7	43.8	46.8
Under 65	66.4	65.9	67.0	67.6	66.9	68.5	57.6	57.4	57.9
65 and over	62.5	62.7	62.4	63.4	63.6	63.3	52.0	52.3	51.9
STAGE:									
All Stages	64.0	64.0	64.0	64.9	64.9	64.9	54.9	55.2	54.7
Localized	89.8	89.7	89.9	90.4	90.3	90.5	84.3	84.5	84.2
Regional	67.7	67.6	67.8	68.5	68.4	68.6	60.6	61.6	59.7
Distant	10.3	9.9	10.7	10.5	10.0	11.1	8.1	8.5	7.8
Unstaged	35.8	39.5	32.5	35.2	39.6	31.2	33.8	33.1	34.1

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table VI-10  
COLON CANCER (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	43	42	44	34	32	35
1970-1973 <sup>a</sup>	-	-	-	49	47	50	37	36	38
1975-1977 <sup>b</sup>	51.4	50.8	52.0	51.6	51.1	52.1	46.3	45.3	46.7
1978-1980 <sup>b</sup>	53.5	52.5	54.3	53.6	52.6	54.5	49.5	47.8	50.6
1981-1983 <sup>b</sup>	56.5	57.0	56.0	56.7	57.5	56.1	49.7	45.9	52.4
1984-1986 <sup>b</sup>	59.1	59.5	58.7	59.8	60.2	59.4	49.9	49.6	50.1
1987-1989 <sup>b</sup>	61.3	61.9	60.7	61.7	62.5	61.0	53.2	51.6	54.5
1990-1992 <sup>b</sup>	63.1	63.6	62.7	63.9	64.4	63.5	54.2	55.8	53.0
1993-1995 <sup>b</sup>	60.8	60.6	60.9	61.4	61.2	61.6	52.3	51.2	53.0
1996-2003 <sup>b</sup>	64.5 <sup>e</sup>	64.7 <sup>e</sup>	64.3 <sup>e</sup>	65.6 <sup>e</sup>	65.8 <sup>e</sup>	65.5 <sup>e</sup>	54.7 <sup>e</sup>	56.1 <sup>e</sup>	53.7 <sup>e</sup>
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	64.0	64.7	63.4	65.2	65.8	64.7	55.6	56.6	54.8
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	124,575	59,772	64,803	101,634	49,027	52,607	13,155	5,847	7,308
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	37	38	36	38	39	37	33	34	33
Regional	37	37	38	37	37	38	36	35	36
Distant	21	21	20	20	21	20	26	26	25
Unstaged	4	4	5	4	4	5	5	5	6
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	64.2	66.0	62.1	66.5	66.3	66.6	55.3	63.3	48.7
45-54	64.8	64.8	64.8	65.7	65.6	65.8	57.6	56.5	58.6
55-64	65.4	65.2	65.6	66.7	66.5	66.9	55.3	55.5	55.2
65-74	65.5	64.9	66.0	66.3	65.4	67.3	57.8	59.4	56.6
75+	60.4	61.3	59.8	61.7	62.8	61.0	46.6	45.5	47.2
Under 65	65.0	65.1	64.8	66.3	66.2	66.5	56.1	56.9	55.3
65 and over	62.9	63.3	62.5	63.9	64.2	63.6	52.8	53.9	52.1
STAGE:									
All Stages	63.5	64.0	63.1	64.6	64.9	64.4	54.3	55.4	53.4
Localized	90.8	91.2	90.5	91.6	91.8	91.3	84.8	85.7	84.0
Regional	69.4	69.7	69.1	70.2	70.6	69.8	62.8	64.6	61.5
Distant	10.8	10.6	11.1	11.1	10.6	11.6	8.4	8.7	8.1
Unstaged	30.0	33.9	26.9	29.9	33.8	26.8	26.2	28.7	24.1

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Rates are based on follow-up of patients into 2004.  
<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.  
<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).  
<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).  
<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.  
<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.  
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table VI-11  
RECTUM CANCER (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	38	36	41	27	28	27
1970-1973 <sup>a</sup>	-	-	-	45	43	48	30	20	40
1975-1977 <sup>b</sup>	49.2	48.1	50.6	49.4	48.4	50.5	44.9	41.7	47.4
1978-1980 <sup>b</sup>	50.4	49.8	51.1	51.2	50.7	51.9	35.4	35.1	35.5
1981-1983 <sup>b</sup>	53.0	51.5	54.8	53.8	52.3	55.4	40.6	38.3	42.9
1984-1986 <sup>b</sup>	57.2	56.4	58.4	58.0	57.3	58.9	46.1	43.3	48.8
1987-1989 <sup>b</sup>	59.1	58.8	59.5	59.6	59.8	59.4	53.5	49.0	58.0
1990-1992 <sup>b</sup>	60.4	59.6	61.5	61.2	60.4	62.2	52.2	54.1	49.8
1993-1995 <sup>b</sup>	61.2	59.9	62.9	61.7	60.4	63.2	54.8	52.1	57.9
1996-2003 <sup>b</sup>	65.8 <sup>e</sup>	65.1 <sup>e</sup>	66.7 <sup>e</sup>	66.4 <sup>e</sup>	65.7 <sup>e</sup>	67.3 <sup>e</sup>	58.4 <sup>e</sup>	57.1 <sup>e</sup>	59.6 <sup>e</sup>
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	65.5	65.0	66.0	66.3	66.1	66.5	56.1	54.7	57.2
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	50,987	28,735	22,252	41,590	23,512	18,078	4,252	2,189	2,063
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	45	44	45	45	44	45	42	40	43
Regional	34	34	34	34	35	34	31	31	30
Distant	15	16	14	15	16	14	18	20	17
Unstaged	6	6	7	6	5	6	9	8	9
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	67.2	63.9	71.3	69.0	66.6	72.0	59.5	52.8	66.7
45-54	70.6	68.3	74.1	71.4	68.7	75.5	64.3	64.3	64.1
55-64	68.0	67.2	69.5	68.7	67.8	70.2	59.4	55.4	64.3
65-74	66.3	64.8	68.3	66.8	65.4	68.7	54.3	51.5	56.7
75+	55.7	55.2	56.1	56.6	56.8	56.4	41.2	37.4	43.4
Under 65	68.8	67.1	71.4	69.7	67.9	72.4	61.2	58.2	64.8
65 and over	61.6	61.1	62.1	62.2	62.1	62.3	49.3	46.7	50.8
STAGE:									
All Stages	65.0	64.1	66.2	65.6	64.9	66.4	56.6	54.5	58.7
Localized	87.8	87.3	88.4	88.0	87.6	88.5	83.0	81.7	84.1
Regional	63.4	63.0	64.0	64.4	63.9	65.1	52.8	53.2	52.0
Distant	8.5	8.0	9.2	8.7	8.2	9.4	7.3	7.9	6.3
Unstaged	44.9	46.5	42.8	43.7	47.0	39.7	45.7	39.0 <sup>f</sup>	51.7 <sup>f</sup>

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Rates are based on follow-up of patients into 2004.  
<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.  
<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).  
<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).  
<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.  
<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.  
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table VII-5  
CORPUS AND UTERUS, NOS CANCER (Invasive)

## SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE

	All Races, Females			White Females			Black Females		
	All	<50	50+	All	<50	50+	All	<50	50+
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	73	-	-	31	-	-
1970-1973 <sup>a</sup>	-	-	-	81	-	-	44	-	-
1975-1977 <sup>b</sup>	87.6	92.7	87.0	88.7	93.3	88.2	61.0	84.4 <sup>f</sup>	56.1
1978-1980 <sup>b</sup>	83.6	91.7	82.5	84.8	93.1	83.8	55.8	82.0 <sup>f</sup>	50.3
1981-1983 <sup>b</sup>	81.9	91.3	80.6	83.3	92.3	82.2	52.5	82.8 <sup>f</sup>	47.2
1984-1986 <sup>b</sup>	83.5	93.6	82.1	85.0	93.9	83.8	57.8	83.6 <sup>f</sup>	54.0
1987-1989 <sup>b</sup>	83.4	90.2	82.3	85.0	91.0	84.1	58.3	84.6 <sup>f</sup>	54.1
1990-1992 <sup>b</sup>	84.5	89.9	83.6	86.7	92.1	85.8	54.9	72.1 <sup>f</sup>	51.1
1993-1995 <sup>b</sup>	84.0	90.1	82.9	85.7	91.6	84.7	60.1	82.0	55.2
1996-2003 <sup>b</sup>	84.3 <sup>e</sup>	89.5 <sup>e</sup>	83.2 <sup>e</sup>	86.2 <sup>e</sup>	90.8	85.4 <sup>e</sup>	61.0	76.7	57.0
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	83.0	89.2	81.7	84.9	90.3	83.8	60.7	78.0	56.7
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	46,771	7,354	39,417	39,689	5,682	34,007	3,452	568	2,884
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	70	73	69	71	73	71	54	66	52
Regional	17	16	17	17	16	17	23	16	24
Distant	9	7	9	8	7	8	16	11	17
Unstaged	4	4	4	4	4	4	7	7	7
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	90.0	-	-	90.7	-	-	82.2	-	-
45-54	88.5	-	-	89.5	-	-	70.7	-	-
55-64	86.0	-	-	88.1	-	-	62.6	-	-
65-74	80.1	-	-	82.9	-	-	52.7	-	-
75+	71.7	-	-	73.9	-	-	45.2	-	-
Under 65	87.5	-	-	89.0	-	-	68.8	-	-
65 and over	76.8	-	-	79.3	-	-	50.3	-	-
STAGE:									
All Stages	82.9	89.1	81.7	84.7	89.9	83.7	60.8	78.6	56.8
Localized	95.3	96.2	95.2	96.1	96.4	96.1	83.2	89.7	81.4
Regional	67.4	80.8	64.9	69.8	83.5	67.4	44.3	63.9 <sup>f</sup>	41.6
Distant	23.1	37.5	20.5	24.9	38.7	22.7	12.7	29.3 <sup>f</sup>	10.6
Unstaged	55.8	85.9	49.2	55.1	85.8	49.1	42.3	78.0 <sup>f</sup>	34.0

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.



Table VIII-5  
ESOPHAGUS CANCER (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	4	4	6	1	0	2
1970-1973 <sup>a</sup>	-	-	-	4	4	4	4	4	3
1975-1977 <sup>b</sup>	5.1	4.0	7.5	5.6	4.9	7.1	3.1	1.6	7.1
1978-1980 <sup>b</sup>	5.2	4.9	5.7	5.6	5.6	5.3	4.3	3.3	7.0
1981-1983 <sup>b</sup>	6.8	6.2	8.4	7.6	6.8	9.3	4.3	3.6	6.5
1984-1986 <sup>b</sup>	9.7	8.5	12.5	10.6	9.3	13.6	8.2	7.6	9.9
1987-1989 <sup>b</sup>	9.8	9.6	10.1	11.0	11.4	9.8	6.4	5.0	10.3
1990-1992 <sup>b</sup>	12.7	12.3	13.8	13.6	12.9	15.4	9.4	9.7	8.4
1993-1995 <sup>b</sup>	12.7	12.8	12.4	14.3	14.5	13.7	7.5	7.6	7.2
1996-2003 <sup>b</sup>	16.4 <sup>e</sup>	16.0 <sup>e</sup>	17.8 <sup>e</sup>	17.5 <sup>e</sup>	17.1 <sup>e</sup>	19.0 <sup>e</sup>	10.9 <sup>e</sup>	9.4 <sup>e</sup>	13.8
<b>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	16.5	15.5	19.8	17.2	16.2	20.5	11.3	10.0	14.1
<b>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></b>									
All Stages									
Number of cases	15,153	11,460	3,693	12,317	9,431	2,886	1,937	1,342	595
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	24	23	25	25	24	26	20	20	21
Regional	30	31	27	30	31	27	29	29	29
Distant	30	32	25	30	31	24	32	33	29
Unstaged	16	14	22	16	14	23	19	17	21
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></b>									
AGE AT DIAGNOSIS:									
<45	21.0	20.0	25.7	20.9	19.7	29.6 <sup>f</sup>	18.4	17.3 <sup>f</sup>	18.3 <sup>f</sup>
45-54	17.2	17.0	18.3	19.3	19.1	19.0	10.3	8.5	16.1
55-64	16.6	15.6	20.9	17.5	16.4	23.3	11.2	10.4	12.5
65-74	15.8	15.5	16.9	16.9	16.6	18.1	6.6	5.7	8.2
75+	11.4	10.8	12.4	12.1	11.4	13.1	9.1	9.9	6.1
Under 65	17.3	16.6	20.8	18.5	17.8	22.9	11.6	10.3	14.5
65 and over	14.1	13.8	14.7	14.9	14.7	15.6	7.4	7.1	7.8
STAGE:									
All Stages	15.6	15.3	16.8	16.6	16.3	17.8	10.1	9.3	11.7
Localized	33.7	34.1	32.1	35.9	36.7	33.0	19.6	16.6	24.5
Regional	16.9	16.2	19.5	18.1	17.6	20.2	11.1	9.3	14.2
Distant	2.9	2.8	3.4	3.1	2.8	4.3	1.5	1.7	-
Unstaged	10.8	10.5	11.2	9.7	8.8	11.1	13.0	14.8	8.9

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
<sup>c</sup> Rates are based on follow-up of patients into 2004.  
<sup>d</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.  
<sup>e</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).  
<sup>f</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).  
<sup>g</sup> The standard error of the survival rate is between 5 and 10 percentage points.  
<sup>h</sup> The standard error of the survival rate is greater than 10 percentage points.  
<sup>i</sup> - Statistic could not be calculated due to fewer than 16 cases during the time period.

Table IX-5  
HODGKIN LYMPHOMA

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE

	<u>All Races</u>			<u>Whites</u>			<u>Blacks</u>		
	<u>Total</u>	<u>Males</u>	<u>Females</u>	<u>Total</u>	<u>Males</u>	<u>Females</u>	<u>Total</u>	<u>Males</u>	<u>Females</u>
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	40	34	48	-	-	-
1970-1973 <sup>a</sup>	-	-	-	67	66	69	-	-	-
1975-1977 <sup>b</sup>	73.5	71.8	75.7	73.9	72.1	76.0	71.3	69.3 <sup>f</sup>	75.3 <sup>f</sup>
1978-1980 <sup>b</sup>	73.4	72.1	75.1	73.6	71.8	75.9	71.4	75.4 <sup>f</sup>	64.0 <sup>f</sup>
1981-1983 <sup>b</sup>	75.7	74.5	77.3	76.1	75.3	77.1	73.4	71.1 <sup>f</sup>	77.5 <sup>f</sup>
1984-1986 <sup>b</sup>	79.3	77.5	81.5	79.8	78.0	82.1	74.8	75.5 <sup>f</sup>	72.3 <sup>f</sup>
1987-1989 <sup>b</sup>	80.4	77.8	83.6	81.0	78.2	84.5	73.0	72.2 <sup>f</sup>	73.9 <sup>f</sup>
1990-1992 <sup>b</sup>	82.9	80.6	85.6	84.0	82.5	85.9	74.2	65.0	84.3
1993-1995 <sup>b</sup>	82.8	80.1	86.0	83.4	81.0	86.2	78.4	74.2	82.7
1996-2003 <sup>b</sup>	86.2 <sup>e</sup>	84.6 <sup>e</sup>	88.1 <sup>e</sup>	87.1 <sup>e</sup>	85.5 <sup>e</sup>	88.9 <sup>e</sup>	80.8 <sup>e</sup>	77.6	84.1
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	84.7	82.9	86.8	84.9	83.3	86.8	82.1	77.4	87.0
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	91.4	89.7	93.4	92.2	90.4	94.3	84.5	81.7	87.5
45-54	83.6	80.9	87.8	84.4	81.9	88.1	76.9	70.1 <sup>f</sup>	86.9 <sup>f</sup>
55-64	71.6	67.9	77.3	71.3	68.9	75.1	71.6 <sup>f</sup>	57.3 <sup>f</sup>	87.8 <sup>f</sup>
65-74	57.2	54.9	59.2	56.7	55.0	57.9	70.1 <sup>f</sup>	62.9 <sup>g</sup>	77.9 <sup>g</sup>
75+	42.1	43.3	40.1	43.9	44.6 <sup>f</sup>	42.4	39.0 <sup>g</sup>	-	-
Under 65	88.7	86.4	91.6	89.4	87.1	92.2	82.6	77.8	88.1
65 and over	51.3	51.2	51.4	51.6	51.7	51.6	59.5 <sup>f</sup>	59.3 <sup>g</sup>	59.6 <sup>g</sup>

- <sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.
- <sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Rates are based on follow-up of patients into 2004.
- <sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.
- <sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).
- <sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).
- <sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.
- <sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table X-6  
KAPOSI SARCOMA

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	<u>All Races</u>			<u>Whites</u>			<u>Blacks</u>		
	<u>Total</u>	<u>Males</u>	<u>Females</u>	<u>Total</u>	<u>Males</u>	<u>Females</u>	<u>Total</u>	<u>Males</u>	<u>Females</u>
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	-	-	-	-	-	-
1970-1973 <sup>a</sup>	-	-	-	-	-	-	-	-	-
1975-1977 <sup>b</sup>	83.2 <sup>f</sup>	82.0 <sup>f</sup>	82.8 <sup>g</sup>	82.0 <sup>f</sup>	80.0 <sup>f</sup>	80.9 <sup>g</sup>	-	-	-
1978-1980 <sup>b</sup>	78.9 <sup>f</sup>	80.6 <sup>f</sup>	72.6 <sup>g</sup>	78.2 <sup>f</sup>	79.2 <sup>f</sup>	72.4 <sup>g</sup>	-	-	-
1981-1983 <sup>b</sup>	33.8	31.1	74.4 <sup>g</sup>	32.1	29.5	72.5 <sup>g</sup>	44.4 <sup>g</sup>	41.5 <sup>g</sup>	-
1984-1986 <sup>b</sup>	12.2	11.1	71.4 <sup>g</sup>	11.8	10.7	70.2 <sup>g</sup>	16.3	15.2	-
1987-1989 <sup>b</sup>	9.8	9.2	65.8 <sup>g</sup>	9.3	8.8	71.4 <sup>g</sup>	11.9	10.8	-
1990-1992 <sup>b</sup>	9.1	8.5	49.4 <sup>f</sup>	8.6	8.1	50.1 <sup>f</sup>	11.5	10.6	-
1993-1995 <sup>b</sup>	21.1	20.6	48.6 <sup>f</sup>	21.6	21.1	57.0 <sup>g</sup>	15.8	15.0	32.5 <sup>g</sup>
1996-2003 <sup>b</sup>	53.6 <sup>e</sup>	53.1 <sup>e</sup>	62.4 <sup>f</sup>	59.1 <sup>e</sup>	58.0 <sup>e</sup>	79.6 <sup>f</sup>	39.0	39.2	38.6 <sup>g</sup>
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	60.3	60.2	62.8	63.1	62.4	71.0	45.6	46.2	-
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	52.1	52.3	42.7 <sup>f</sup>	54.7	54.5	67.1 <sup>g</sup>	40.8	41.7	22.9 <sup>f</sup>
45-54	52.5	53.1	35.6 <sup>g</sup>	52.9	53.1	-	47.1 <sup>f</sup>	48.2 <sup>f</sup>	-
55-64	69.7	69.6	-	69.5	69.0	-	53.2 <sup>g</sup>	52.6 <sup>g</sup>	-
65-74	77.5 <sup>f</sup>	80.5 <sup>f</sup>	67.2 <sup>g</sup>	79.3 <sup>f</sup>	80.4 <sup>f</sup>	74.0 <sup>g</sup>	-	-	-
75+	88.3 <sup>f</sup>	90.9 <sup>f</sup>	78.6 <sup>f</sup>	90.2 <sup>f</sup>	93.0 <sup>f</sup>	81.1 <sup>g</sup>	81.7 <sup>g</sup>	-	-
Under 65	53.2	53.4	44.9 <sup>f</sup>	55.3	55.2	63.6 <sup>f</sup>	42.3	43.1	25.7 <sup>f</sup>
65 and over	84.0	86.4 <sup>f</sup>	77.3 <sup>f</sup>	85.9	87.4 <sup>f</sup>	80.8 <sup>f</sup>	66.5 <sup>g</sup>	39.8 <sup>g</sup>	-

- <sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.
- <sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).
- <sup>c</sup> Rates are based on follow-up of patients into 2004.
- <sup>d</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.
- <sup>e</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).
- <sup>f</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).
- <sup>g</sup> The standard error of the survival rate is between 5 and 10 percentage points.
- The standard error of the survival rate is greater than 10 percentage points.
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XI-5  
KIDNEY AND RENAL PELVIS CANCER (Invasive)

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	37	36	39	38	38	37
1970-1973 <sup>a</sup>	-	-	-	46	44	50	44	40	49
1975-1977 <sup>b</sup>	50.9	51.0	50.8	50.7	50.9	50.3	50.1	48.9	52.0 <sup>f</sup>
1978-1980 <sup>b</sup>	54.0	53.8	54.3	53.8	54.0	53.2	57.1	52.0	63.4 <sup>f</sup>
1981-1983 <sup>b</sup>	51.4	52.2	50.0	51.3	52.4	49.5	51.9	51.8	52.0
1984-1986 <sup>b</sup>	55.8	56.2	55.1	56.0	56.6	55.0	54.0	50.5	59.1
1987-1989 <sup>b</sup>	57.9	58.2	57.4	58.5	59.2	57.4	55.8	53.2	58.6
1990-1992 <sup>b</sup>	61.5	61.7	61.2	62.1	62.5	61.5	57.6	55.8	59.4
1993-1995 <sup>b</sup>	62.6	62.4	62.9	63.1	63.5	62.4	58.6	55.2	63.5
1996-2003 <sup>b</sup>	65.7 <sup>e</sup>	64.6 <sup>e</sup>	67.3 <sup>e</sup>	65.5 <sup>e</sup>	64.8 <sup>e</sup>	66.7 <sup>e</sup>	65.5 <sup>e</sup>	63.0 <sup>e</sup>	67.5 <sup>e</sup>
<b>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	67.0	66.4	68.0	67.0	66.7	67.6	63.9	60.6	67.8
<b>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></b>									
All Stages									
Number of cases	40,169	24,669	15,500	33,646	20,747	12,899	4,001	2,347	1,654
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	55	54	57	55	54	57	59	59	60
Regional	19	20	18	20	21	19	16	16	15
Distant	20	21	19	20	21	19	20	20	19
Unstaged	5	4	6	5	4	6	6	5	6
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></b>									
AGE AT DIAGNOSIS:									
<45	79.7	77.2	83.0	80.9	78.8	84.0	72.1	66.6	77.9
45-54	70.9	68.7	75.6	71.0	68.7	76.2	67.4	65.0	71.2
55-64	66.4	65.7	67.9	66.8	66.1	68.2	63.2	60.5	66.5
65-74	62.5	61.9	63.5	62.4	61.7	63.4	61.4	61.0	60.9
75+	51.8	53.6	50.0	52.0	54.4	49.6	48.0	47.0 <sup>f</sup>	48.1
Under 65	70.9	69.0	74.4	71.2	69.4	74.7	67.4	63.9	72.1
65 and over	58.3	58.9	57.5	58.2	59.1	57.2	57.0	57.4	55.6
STAGE:									
All Stages	65.5	65.1	66.3	65.5	65.3	66.0	64.2	62.0	66.3
Localized	89.6	89.3	90.0	90.0	89.8	90.3	85.4	83.7	86.8
Regional	60.8	62.4	57.9	60.7	62.5	57.5	57.0	55.8	57.4
Distant	9.5	9.5	9.6	9.4	9.7	8.9	10.3	7.6	14.2
Unstaged	35.2	37.3	32.1	33.1	36.3	28.5	38.5	34.2 <sup>f</sup>	41.2 <sup>f</sup>

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XII-5  
LARYNX CANCER (Invasive)

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	53	54	46	-	-	-
1970-1973 <sup>a</sup>	-	-	-	62	63	56	-	-	-
1975-1977 <sup>b</sup>	66.6	67.2	62.8	67.2	68.0	62.5	59.2	58.3	63.5 <sup>f</sup>
1978-1980 <sup>b</sup>	66.0	66.3	64.5	67.0	67.3	65.3	57.1	57.3	56.0 <sup>f</sup>
1981-1983 <sup>b</sup>	68.8	69.0	68.0	70.3	70.5	69.5	56.5	57.3	53.1 <sup>f</sup>
1984-1986 <sup>b</sup>	65.7	66.4	62.3	67.6	68.3	64.2	52.8	53.4	50.8 <sup>f</sup>
1987-1989 <sup>b</sup>	66.4	67.4	62.4	67.7	69.3	61.7	57.0	54.9	63.2 <sup>f</sup>
1990-1992 <sup>b</sup>	66.5	67.3	63.3	68.4	69.1	65.4	53.2	53.7	51.1 <sup>f</sup>
1993-1995 <sup>b</sup>	63.9	65.5	57.3	65.5	67.3	58.2	53.0	54.2	48.0 <sup>f</sup>
1996-2003 <sup>b</sup>	63.7 <sup>e</sup>	65.1	58.8	66.0	67.2	61.6	50.1	52.0	44.8
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	62.6	63.7	58.2	63.8	64.7	60.6	53.0	55.3	45.2
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	13,218	10,573	2,645	10,632	8,484	2,148	1,953	1,546	407
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	47	48	45	49	50	47	38	37	40
Regional	42	42	45	41	41	44	49	49	49
Distant	7	7	6	6	6	6	10	11	9
Unstaged	3	3	4	4	3	4	3	3	3
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	72.7	70.7	77.2	75.3	73.0	80.2	61.4	59.3 <sup>f</sup>	64.5 <sup>f</sup>
45-54	64.0	64.2	63.0	67.3	67.4	66.6	49.9	49.2	51.7 <sup>f</sup>
55-64	63.1	64.1	59.3	64.9	65.8	61.5	53.1	54.5	48.5 <sup>f</sup>
65-74	62.3	64.4	54.8	63.0	64.5	57.3	50.2	57.4	23.3 <sup>f</sup>
75+	57.3	60.4	47.0	58.3	61.2	49.0	47.7 <sup>f</sup>	49.2 <sup>f</sup>	36.6 <sup>g</sup>
Under 65	64.4	64.7	63.2	66.8	67.0	66.0	52.8	53.1	52.1
65 and over	61.1	63.4	52.4	61.7	63.7	54.8	49.5	55.2	28.7 <sup>f</sup>
STAGE:									
All Stages	62.9	64.1	58.3	64.4	65.4	60.7	51.8	53.8	45.2
Localized	81.1	82.6	75.1	82.3	83.6	77.1	71.4	74.6	60.9 <sup>f</sup>
Regional	50.0	50.6	47.9	50.5	50.8	49.4	44.6	46.4	39.1
Distant	23.9	24.8	17.9	24.4	25.3	19.0 <sup>f</sup>	21.1	22.0	17.5 <sup>f</sup>
Unstaged	45.7	48.5	36.8 <sup>f</sup>	46.4	48.9	38.7 <sup>f</sup>	28.1 <sup>f</sup>	35.8 <sup>g</sup>	-

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XIII-11  
LEUKEMIA

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	14	-	-	-	-	-
1970-1973 <sup>a</sup>	-	-	-	22	-	-	-	-	-
1975-1977 <sup>b</sup>	35.4	34.3	36.7	35.9	35.0	37.1	33.5	30.4	36.7
1978-1980 <sup>b</sup>	37.8	36.8	39.1	38.5	37.7	39.6	29.4	28.5	30.5
1981-1983 <sup>b</sup>	39.2	39.0	39.6	40.2	40.0	40.4	34.3	33.7	35.0
1984-1986 <sup>b</sup>	41.8	41.3	42.5	43.1	42.6	43.7	33.8	32.7	35.0
1987-1989 <sup>b</sup>	44.4	45.9	42.5	45.5	47.4	42.9	36.9	35.0	39.2
1990-1992 <sup>b</sup>	46.6	46.3	47.0	48.0	48.2	47.7	37.4	31.6	43.7
1993-1995 <sup>b</sup>	48.4	49.1	47.5	49.3	50.0	48.5	42.0	41.6	42.5
1996-2003 <sup>b</sup>	49.8 <sup>e</sup>	50.0 <sup>e</sup>	49.6 <sup>e</sup>	50.8 <sup>e</sup>	50.8 <sup>e</sup>	50.8 <sup>e</sup>	40.3	40.6	39.9
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	50.9	51.3	50.3	51.2	51.6	50.7	42.6	42.1	42.8
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	66.0	64.8	67.7	67.5	66.3	69.2	53.9	52.0	56.2
45-54	55.6	57.6	52.6	56.9	58.1	55.0	44.8	49.9	39.1
55-64	52.6	52.6	52.6	54.5	54.4	54.5	34.2	30.2	38.4
65-74	41.6	40.2	43.6	42.6	40.9	45.0	32.5	32.1	33.3
75+	29.3	28.4	30.1	30.0	28.9	31.0	24.1	20.3	24.9
Under 65	60.0	59.7	60.6	61.4	60.9	62.3	47.0	46.4	47.7
65 and over	35.4	34.8	36.0	36.1	35.4	36.9	28.9	28.7	28.9

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XIII-12  
LYMPHOCYTIC LEUKEMIA

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>ACUTE LYMPHOCYTIC LEUKEMIA</b>									
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1975-1977 <sup>a</sup>	42.2	38.3	47.4	42.6	38.9	47.9	34.5 <sup>e</sup>	-	38.9 <sup>f</sup>
1978-1980 <sup>a</sup>	50.4	46.8	55.6	50.7	47.4	55.4	31.7 <sup>e</sup>	31.4 <sup>e</sup>	-
1981-1983 <sup>a</sup>	52.0	48.7	56.4	52.8	49.6	57.2	43.4 <sup>e</sup>	37.6 <sup>e</sup>	49.1 <sup>e</sup>
1984-1986 <sup>a</sup>	53.4	50.3	57.7	54.4	50.5	59.9	36.0 <sup>e</sup>	43.6 <sup>e</sup>	27.4 <sup>e</sup>
1987-1989 <sup>a</sup>	56.1	55.7	56.6	56.8	57.0	56.4	46.1 <sup>e</sup>	43.1 <sup>e</sup>	48.0 <sup>e</sup>
1990-1992 <sup>a</sup>	59.8	56.4	64.6	59.7	57.1	63.5	59.3 <sup>e</sup>	54.2 <sup>e</sup>	63.8 <sup>e</sup>
1993-1995 <sup>a</sup>	61.6	58.8	65.3	61.0	58.7	64.2	53.9 <sup>e</sup>	45.7 <sup>e</sup>	65.0 <sup>e</sup>
1996-2003 <sup>a</sup>	65.3 <sup>d</sup>	63.5 <sup>d</sup>	67.6 <sup>d</sup>	66.4 <sup>d</sup>	64.5 <sup>d</sup>	68.7 <sup>d</sup>	56.5 <sup>d</sup>	53.2 <sup>e</sup>	61.1 <sup>e</sup>
<b>5-YR PERIOD SURVIVAL RATES<sup>bc</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	64.0	62.4	66.0	64.8	63.7	66.2	55.0	46.4	66.1
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>b</sup></b>									
AGE AT DIAGNOSIS:									
<45	73.9	71.0	77.7	74.9	72.1	78.7	62.8	57.1	69.9
45-54	24.5	27.0	21.5	23.9	26.9	19.4	13.7 <sup>e</sup>	26.8 <sup>f</sup>	-
55-64	15.9	13.8	18.6	13.7	12.4	15.6	20.9 <sup>f</sup>	-	-
65-74	7.7	6.0	8.7	8.5	6.6	9.9	-	-	-
75+	5.8	1.8	8.1	4.6	0.0	7.5	-	-	-
Under 65	68.1	65.7	71.3	68.8	66.4	71.9	58.1	53.3	64.3
65 and over	7.0	4.7	8.5	6.9	4.1	8.8	9.0 <sup>e</sup>	-	-
<b>CHRONIC LYMPHOCYTIC LEUKEMIA</b>									
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1975-1977 <sup>a</sup>	69.0	66.8	71.8	69.8	67.5	72.8	57.2 <sup>e</sup>	56.3 <sup>e</sup>	57.9 <sup>e</sup>
1978-1980 <sup>a</sup>	70.7	67.9	74.3	71.4	68.5	75.3	59.2 <sup>e</sup>	59.6 <sup>e</sup>	58.4 <sup>e</sup>
1981-1983 <sup>a</sup>	68.4	67.9	69.1	69.1	68.9	69.4	57.6 <sup>e</sup>	54.3 <sup>e</sup>	62.9 <sup>e</sup>
1984-1986 <sup>a</sup>	73.8	72.5	75.7	74.1	72.6	76.0	70.1 <sup>e</sup>	67.3 <sup>e</sup>	70.5 <sup>e</sup>
1987-1989 <sup>a</sup>	74.5	74.5	74.5	75.5	75.6	75.3	60.4	59.0 <sup>e</sup>	62.5 <sup>e</sup>
1990-1992 <sup>a</sup>	75.5	74.2	77.3	76.6	75.5	78.2	54.0 <sup>e</sup>	45.3 <sup>e</sup>	62.7 <sup>e</sup>
1993-1995 <sup>a</sup>	77.4	76.8	78.1	78.2	77.5	79.1	64.4	63.0 <sup>e</sup>	66.4 <sup>e</sup>
1996-2003 <sup>a</sup>	74.8 <sup>d</sup>	73.4 <sup>d</sup>	77.0 <sup>d</sup>	75.5 <sup>d</sup>	73.9 <sup>d</sup>	77.8	58.3	52.6	64.5 <sup>e</sup>
<b>5-YR PERIOD SURVIVAL RATES<sup>bc</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	75.6	74.7	77.0	75.7	74.9	77.0	62.2	58.0	67.7
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>b</sup></b>									
AGE AT DIAGNOSIS:									
<45	87.8	88.4	86.1	90.0	89.5	91.2	63.8 <sup>f</sup>	78.6 <sup>f</sup>	52.7 <sup>f</sup>
45-54	83.4	81.7	86.6	84.4	82.1	89.1	67.8 <sup>e</sup>	65.3 <sup>e</sup>	73.5 <sup>e</sup>
55-64	82.1	78.6	88.8	83.3	80.9	88.0	60.3	43.6 <sup>e</sup>	87.1 <sup>e</sup>
65-74	75.8	71.8	81.9	76.4	72.5	82.3	58.8 <sup>e</sup>	55.9 <sup>e</sup>	63.8 <sup>e</sup>
75+	60.6	59.3	61.9	61.1	59.1	62.9	46.3 <sup>e</sup>	37.0 <sup>e</sup>	49.8 <sup>e</sup>
Under 65	83.1	80.6	87.9	84.3	82.2	88.7	63.8	55.5	77.7 <sup>e</sup>
65 and over	68.4	66.5	70.8	68.9	66.7	71.4	53.6	50.6 <sup>e</sup>	56.3 <sup>e</sup>

<sup>a</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Rates are based on follow-up of patients into 2004.

<sup>b</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>c</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>d</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).

<sup>e</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>f</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XIII-13  
MYELOID LEUKEMIA

	SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE								
	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>ACUTE MYELOID LEUKEMIA</b>									
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1975-1977 <sup>a</sup>	6.6	6.1	7.1	6.3	6.1	6.5	10.6	8.5 <sup>e</sup>	12.1 <sup>e</sup>
1978-1980 <sup>a</sup>	8.4	7.9	9.0	7.8	6.9	8.8	10.2	7.2	13.2
1981-1983 <sup>a</sup>	9.5	8.3	10.8	8.7	7.3	10.4	12.5	16.4 <sup>e</sup>	8.8
1984-1986 <sup>a</sup>	12.0	10.5	13.7	11.8	10.4	13.3	10.2	6.9	13.3
1987-1989 <sup>a</sup>	12.8	10.5	15.3	12.7	11.2	14.4	10.1	4.7	16.9 <sup>e</sup>
1990-1992 <sup>a</sup>	15.3	13.8	16.9	15.0	13.5	16.8	14.6	14.3	14.7
1993-1995 <sup>a</sup>	18.0	16.5	19.6	17.4	15.8	19.2	23.0	22.7 <sup>e</sup>	22.5
1996-2003 <sup>a</sup>	20.7 <sup>d</sup>	19.6 <sup>d</sup>	22.0 <sup>d</sup>	20.0 <sup>d</sup>	18.4 <sup>d</sup>	21.6 <sup>d</sup>	22.6 <sup>d</sup>	26.5 <sup>d</sup>	17.7
<b>5-YR PERIOD SURVIVAL RATES<sup>bc</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	21.8	20.9	22.8	21.1	19.9	22.4	22.8	25.3	19.2
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>b</sup></b>									
AGE AT DIAGNOSIS:									
<45	49.4	47.7	51.4	50.1	48.8	51.5	41.7	41.8	41.4 <sup>e</sup>
45-54	26.5	25.6	27.6	26.8	24.4	29.8	25.0	28.1 <sup>e</sup>	22.2 <sup>e</sup>
55-64	17.3	15.3	19.6	17.7	15.5	20.5	9.3	-	9.8 <sup>e</sup>
65-74	6.8	5.8	8.1	7.0	6.1	8.1	5.7	6.1	0.0
75+	1.7	1.1	2.2	1.7	1.0	2.1	2.4	-	1.7
Under 65	34.9	33.1	37.2	35.0	32.7	37.6	30.8	32.1	28.8
65 and over	4.1	3.6	4.7	4.1	3.6	4.6	4.1	5.7	2.1
<b>CHRONIC MYELOID LEUKEMIA</b>									
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1975-1977 <sup>a</sup>	23.9	21.5	27.1	22.6	20.5	25.5	28.7 <sup>e</sup>	22.6 <sup>e</sup>	36.0 <sup>e</sup>
1978-1980 <sup>a</sup>	25.3	24.4	26.2	25.5	25.3	25.7	22.0 <sup>e</sup>	20.9 <sup>e</sup>	23.6 <sup>e</sup>
1981-1983 <sup>a</sup>	30.5	26.5	35.2	31.1	27.5	35.0	30.2	20.6 <sup>e</sup>	41.3 <sup>e</sup>
1984-1986 <sup>a</sup>	23.8	21.6	26.9	24.4	21.7	28.3	22.5	21.9 <sup>e</sup>	22.6 <sup>e</sup>
1987-1989 <sup>a</sup>	32.4	32.9	31.5	32.2	33.4	30.5	36.9 <sup>e</sup>	30.3 <sup>e</sup>	45.0 <sup>e</sup>
1990-1992 <sup>a</sup>	32.3	31.0	34.1	32.1	32.2	32.0	34.9 <sup>e</sup>	22.1 <sup>e</sup>	48.3 <sup>e</sup>
1993-1995 <sup>a</sup>	37.1	36.8	37.5	36.9	37.0	36.9	34.9 <sup>e</sup>	32.8 <sup>e</sup>	38.6 <sup>e</sup>
1996-2003 <sup>a</sup>	44.4 <sup>d</sup>	43.1 <sup>d</sup>	46.1 <sup>d</sup>	44.0 <sup>d</sup>	42.3 <sup>d</sup>	46.0 <sup>d</sup>	40.2	40.6 <sup>e</sup>	40.0 <sup>e</sup>
<b>5-YR PERIOD SURVIVAL RATES<sup>bc</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	52.3	52.2	52.3	51.3	50.5	52.2	50.5	48.9	52.0
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>b</sup></b>									
AGE AT DIAGNOSIS:									
<45	67.9	66.3	70.5	68.6	65.8	73.3	62.7	61.9 <sup>e</sup>	64.4 <sup>e</sup>
45-54	65.3	62.8	68.1	66.1	62.8	69.4	56.1 <sup>e</sup>	56.7 <sup>e</sup>	54.5 <sup>f</sup>
55-64	54.4	52.8	56.8	57.7	54.3	63.3	28.5 <sup>e</sup>	38.9 <sup>e</sup>	13.4 <sup>f</sup>
65-74	29.8	28.6	31.6	28.9	27.3	31.4	27.7 <sup>e</sup>	24.4 <sup>e</sup>	29.7 <sup>e</sup>
75+	18.7	17.5	19.9	18.3	16.5	20.3	18.0 <sup>e</sup>	7.3 <sup>e</sup>	19.6 <sup>f</sup>
Under 65	63.6	61.8	66.3	64.9	61.8	69.4	53.2	55.0	50.9 <sup>e</sup>
65 and over	24.3	23.5	25.4	23.4	22.2	25.1	24.7 <sup>e</sup>	20.6 <sup>e</sup>	27.3 <sup>e</sup>

<sup>a</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta). Rates are based on follow-up of patients into 2004.

<sup>b</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>c</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>d</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>e</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>f</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.



Table XIV-5  
LIVER AND INTRAHEPATIC BILE DUCT CANCER (Invasive)

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	-	-	-	-	-	-
1970-1973 <sup>a</sup>	-	-	-	-	-	-	-	-	-
1975-1977 <sup>b</sup>	3.7	2.0	6.7	3.7	2.1	6.1	1.9	0.0	5.9
1978-1980 <sup>b</sup>	3.5	2.3	5.5	3.4	2.3	4.8	3.8	3.2	5.1
1981-1983 <sup>b</sup>	3.9	3.2	5.3	4.3	3.5	5.6	3.0	2.1	4.9
1984-1986 <sup>b</sup>	6.0	3.7	10.2	6.0	3.7	10.0	4.5	2.2	9.7 <sup>f</sup>
1987-1989 <sup>b</sup>	5.2	3.4	8.7	6.1	3.6	10.2	3.4	2.5	5.1
1990-1992 <sup>b</sup>	5.9	5.1	7.5	6.8	5.6	8.9	2.7	2.0	3.7
1993-1995 <sup>b</sup>	5.8	5.4	6.7	5.5	5.1	6.1	4.2	2.8	7.8
1996-2003 <sup>b</sup>	10.5 <sup>e</sup>	10.0 <sup>e</sup>	11.5 <sup>e</sup>	9.9 <sup>e</sup>	9.1 <sup>e</sup>	11.7 <sup>e</sup>	7.6 <sup>e</sup>	8.1	6.3
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	12.1	11.8	12.6	11.5	11.3	12.2	8.5	8.8	7.5
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	21,404	14,774	6,630	14,252	9,737	4,515	2,253	1,606	647
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	33	34	33	33	34	32	31	30	33
Regional	25	26	23	24	25	22	28	29	26
Distant	20	20	20	20	20	21	23	24	23
Unstaged	21	20	23	23	21	26	18	18	19
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	23.4	19.2	33.2	26.5	20.2	38.9	15.2	17.8	11.1 <sup>f</sup>
45-54	14.0	13.3	17.2	15.6	14.8	19.1	5.2	4.7	9.3
55-64	10.8	10.1	12.8	10.6	9.8	13.0	7.6	7.2	9.0
65-74	8.7	8.6	8.9	7.0	6.3	8.4	6.8	8.9	3.6
75+	4.7	4.1	5.3	4.2	3.5	4.6	-	-	-
Under 65	14.1	12.8	18.7	15.1	13.4	21.0	7.6	7.4	8.8
65 and over	7.0	6.9	7.1	5.7	5.2	6.4	5.5	6.9	3.1
STAGE:									
All Stages	10.8	10.4	11.7	10.4	9.8	11.7	7.0	7.6	5.5
Localized	22.3	21.8	23.4	22.4	21.2	24.9	15.6	19.3	5.6
Regional	7.3	7.2	7.7	6.9	6.5	7.9	4.3	3.5	6.9
Distant	2.8	2.2	3.9	2.4	1.6	4.2	2.1	2.5	1.2
Unstaged	4.4	3.8	5.4	4.0	3.7	4.5	3.5	1.7	7.1

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XV-9  
LUNG AND BRONCHUS CANCER (Invasive)

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	8	7	11	5	5	6
1970-1973 <sup>a</sup>	-	-	-	10	9	14	7	6	10
1975-1977 <sup>b</sup>	12.7	11.5	15.8	12.8	11.5	15.9	11.5	10.7	14.0
1978-1980 <sup>b</sup>	13.3	11.8	16.6	13.4	12.0	16.6	12.0	10.0	17.9
1981-1983 <sup>b</sup>	13.7	12.1	16.9	13.9	12.3	17.1	11.7	10.5	14.9
1984-1986 <sup>b</sup>	13.3	11.6	16.3	13.5	11.7	16.7	11.4	10.6	13.0
1987-1989 <sup>b</sup>	13.6	12.4	15.4	13.8	12.5	15.8	11.2	11.1	11.5
1990-1992 <sup>b</sup>	14.1	12.6	16.3	14.5	13.0	16.6	10.8	9.6	12.8
1993-1995 <sup>b</sup>	14.8	12.9	17.4	15.1	13.1	17.7	13.0	11.5	15.8
1996-2003 <sup>b</sup>	15.5 <sup>e</sup>	13.4 <sup>e</sup>	17.9 <sup>e</sup>	15.7 <sup>e</sup>	13.6 <sup>e</sup>	18.1 <sup>e</sup>	12.5 <sup>e</sup>	10.8	14.9
<b>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	15.1	12.9	17.7	15.4	13.2	17.8	12.1	10.3	14.7
<b>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></b>									
All Stages									
Number of cases	209,212	115,421	93,791	173,860	93,945	79,915	22,088	13,287	8,801
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	16	15	18	16	15	18	14	13	15
Regional	35	35	35	35	35	34	36	36	37
Distant	41	43	39	41	42	39	43	45	41
Unstaged	8	7	8	8	7	8	7	6	7
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></b>									
AGE AT DIAGNOSIS:									
<45	23.1	20.8	25.4	25.2	23.7	26.7	14.8	11.5	18.8
45-54	17.8	14.3	22.2	18.5	14.7	23.2	13.7	11.6	17.3
55-64	17.0	14.6	20.3	17.5	15.1	20.6	13.3	11.1	17.1
65-74	15.0	13.0	17.5	15.2	13.2	17.7	11.0	9.6	12.9
75+	10.5	9.2	11.7	10.7	9.3	11.9	8.3	7.0	9.6
Under 65	17.7	15.0	21.4	18.4	15.6	21.9	13.7	11.4	17.4
65 and over	13.2	11.5	15.0	13.3	11.7	15.1	10.1	8.8	11.7
STAGE:									
All Stages	15.0	13.0	17.4	15.3	13.2	17.6	12.0	10.2	14.6
Localized	49.1	44.6	53.4	49.8	45.4	53.8	40.4	36.7	44.7
Regional	15.2	13.9	16.8	15.5	14.2	16.9	12.9	10.9	15.7
Distant	3.0	2.7	3.4	2.9	2.5	3.4	2.8	2.6	3.1
Unstaged	8.1	7.6	8.7	7.8	7.1	8.5	8.5	8.7	8.2

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XV-10  
SMALL CELL LUNG AND BRONCHUS CANCER (Invasive)

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1975-1977 <sup>a</sup>	3.7	3.1	4.8	3.7	3.1	4.9	3.8	3.9	3.6
1978-1980 <sup>a</sup>	4.4	3.3	6.6	4.5	3.5	6.5	3.2	2.4	5.0
1981-1983 <sup>a</sup>	4.8	3.8	6.4	4.9	3.9	6.3	5.6	4.3	8.5
1984-1986 <sup>a</sup>	4.7	3.5	6.4	4.9	3.7	6.6	3.6	2.3	5.6
1987-1989 <sup>a</sup>	5.2	4.0	6.7	5.3	4.0	6.9	4.0	3.4	4.7
1990-1992 <sup>a</sup>	5.6	4.8	6.6	5.7	4.8	6.8	4.2	4.4	3.9
1993-1995 <sup>a</sup>	6.6	5.4	8.0	6.5	5.3	7.8	6.9	4.6	9.9
1996-2003 <sup>a</sup>	6.2 <sup>d</sup>	5.3 <sup>d</sup>	7.0 <sup>d</sup>	6.2 <sup>d</sup>	5.1 <sup>d</sup>	7.2 <sup>d</sup>	4.8 <sup>d</sup>	4.8 <sup>d</sup>	4.7
<b>5-YR PERIOD SURVIVAL RATES<sup>bc</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	5.9	5.3	6.5	5.9	5.1	6.7	4.8	5.6	4.0
<b>STAGE DISTRIBUTION (%) 1996-2003<sup>b</sup></b>									
All Stages									
Number of cases	29,144	15,049	14,095	25,504	12,906	12,598	2,317	1,260	1,057
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	6	6	6	6	6	6	6	6	6
Regional	33	31	35	33	30	35	35	35	36
Distant	56	59	54	57	60	53	54	55	54
Unstaged	5	4	5	5	4	5	4	4	5
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>b</sup></b>									
AGE AT DIAGNOSIS:									
<45	9.0	7.6	10.4	9.5	7.6	11.4	-	-	0.0
45-54	8.3	6.4	10.6	8.5	6.9	10.4	6.3	2.8	10.7
55-64	7.4	6.3	8.5	7.4	6.2	8.6	5.2	4.9	5.6
65-74	4.9	4.2	5.6	4.9	3.9	5.8	4.0	5.0	2.9
75+	2.8	2.3	3.2	2.9	2.6	3.2	1.4	1.1	2.0
Under 65	7.7	6.5	9.2	7.8	6.5	9.2	5.3	4.3	6.8
65 and over	4.2	3.6	4.7	4.2	3.5	4.9	3.2	3.7	2.6
STAGE:									
All Stages	5.7	4.9	6.6	5.8	4.9	6.7	4.3	3.9	4.7
Localized	18.9	17.3	20.3	18.5	17.3	19.6	17.7	19.9 <sup>e</sup>	13.2 <sup>e</sup>
Regional	9.9	9.2	10.4	10.2	9.4	10.9	6.3	6.3	6.4
Distant	1.9	1.4	2.4	1.8	1.4	2.4	0.8	0.0	2.3
Unstaged	6.5	5.8	7.0	6.4	6.1	6.7	7.1	-	8.6

<sup>a</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>b</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>c</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>d</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>e</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>f</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XV-11  
NON-SMALL CELL LUNG AND BRONCHUS CANCER (Invasive)

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1975-1977 <sup>a</sup>	14.2	12.7	17.9	14.3	12.8	18.1	12.5	11.4	16.2
1978-1980 <sup>a</sup>	15.0	13.4	18.9	15.3	13.6	18.9	13.2	10.9	19.9
1981-1983 <sup>a</sup>	15.6	13.7	19.5	16.0	14.0	19.9	12.5	11.3	15.9
1984-1986 <sup>a</sup>	15.1	13.2	18.8	15.5	13.4	19.2	12.6	11.8	14.6
1987-1989 <sup>a</sup>	15.4	14.0	17.6	15.8	14.2	18.2	12.3	12.1	12.7
1990-1992 <sup>a</sup>	15.8	14.0	18.6	16.4	14.6	19.1	11.7	10.2	14.4
1993-1995 <sup>a</sup>	16.4	14.2	19.4	16.8	14.5	20.0	13.8	12.3	16.7
1996-2003 <sup>a</sup>	17.1 <sup>d</sup>	14.7 <sup>d</sup>	20.1 <sup>d</sup>	17.5 <sup>d</sup>	15.1 <sup>d</sup>	20.4 <sup>d</sup>	13.4	11.5	16.4
<b>5-YR PERIOD SURVIVAL RATES<sup>bc</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	16.6	14.0	19.7	17.0	14.5	20.0	12.9	10.8	16.1
<b>STAGE DISTRIBUTION (%) 1996-2003<sup>b</sup></b>									
All Stages									
Number of cases	180,068	100,372	79,696	148,356	81,039	67,317	19,771	12,027	7,744
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	18	16	20	18	16	20	15	13	17
Regional	35	36	35	35	36	34	37	36	37
Distant	39	40	37	38	40	37	42	44	39
Unstaged	8	8	9	8	8	9	7	7	7
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>b</sup></b>									
AGE AT DIAGNOSIS:									
<45	24.8	22.5	27.3	27.4	26.1	28.8	15.7	11.9	20.5
45-54	19.4	15.6	24.4	20.4	16.1	25.9	14.5	12.5	18.1
55-64	19.0	16.1	23.1	19.8	16.8	23.7	14.4	11.8	18.8
65-74	16.8	14.4	19.9	17.2	14.7	20.2	11.9	10.1	14.5
75+	11.5	10.0	12.9	11.7	10.2	13.1	9.0	7.6	10.4
Under 65	19.6	16.4	23.9	20.6	17.3	24.8	14.6	12.1	18.8
65 and over	14.6	12.7	16.7	14.8	12.9	17.0	10.9	9.3	13.0
STAGE:									
All Stages	16.5	14.2	19.4	17.0	14.6	19.7	12.9	10.8	15.9
Localized	50.8	46.1	55.4	51.6	47.0	55.9	41.4	37.4	46.1
Regional	16.1	14.5	18.0	16.3	14.9	18.1	13.6	11.4	16.9
Distant	3.2	2.9	3.7	3.2	2.8	3.7	3.0	2.9	3.2
Unstaged	8.3	7.7	9.0	7.9	7.2	8.7	8.6	8.9	8.0

<sup>a</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>b</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>c</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>d</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>e</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>f</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XVI-5  
MELANOMA OF THE SKIN (Invasive)

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	60	51	68	-	-	-
1970-1973 <sup>a</sup>	-	-	-	68	62	75	-	-	-
1975-1977 <sup>b</sup>	82.3	77.9	86.7	82.3	77.9	86.7	59.7 <sup>f</sup>	47.7 <sup>g</sup>	68.1 <sup>g</sup>
1978-1980 <sup>b</sup>	83.2	78.2	88.1	83.3	78.2	88.2	59.7 <sup>g</sup>	-	69.5 <sup>g</sup>
1981-1983 <sup>b</sup>	83.4	79.0	87.8	83.3	78.9	87.7	60.8 <sup>g</sup>	51.5 <sup>g</sup>	68.3 <sup>g</sup>
1984-1986 <sup>b</sup>	86.8	82.7	91.2	86.5	82.2	91.1	69.7 <sup>g</sup>	-	71.7 <sup>g</sup>
1987-1989 <sup>b</sup>	88.4	85.3	91.7	88.2	85.3	91.4	79.9 <sup>f</sup>	61.7 <sup>g</sup>	90.4 <sup>f</sup>
1990-1992 <sup>b</sup>	89.6	87.3	92.1	89.6	87.2	92.1	60.3 <sup>f</sup>	53.3 <sup>g</sup>	68.0 <sup>g</sup>
1993-1995 <sup>b</sup>	89.8	87.2	92.8	89.6	86.9	92.8	66.8 <sup>f</sup>	65.4 <sup>g</sup>	66.9 <sup>g</sup>
1996-2003 <sup>b</sup>	91.9 <sup>e</sup>	90.0 <sup>e</sup>	94.1 <sup>e</sup>	91.7 <sup>e</sup>	89.7 <sup>e</sup>	94.1 <sup>e</sup>	77.0	75.5 <sup>f</sup>	77.5 <sup>f</sup>
<b>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	91.2	88.8	94.0	90.9	88.5	93.9	70.6	67.3	72.3
<b>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></b>									
All Stages									
Number of cases	61,909	34,108	27,801	58,323	32,262	26,061	313	148	165
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	80	78	83	80	78	83	58	53	62
Regional	12	14	11	13	14	11	23	24	23
Distant	3	4	2	4	4	2	12	16	9
Unstaged	4	4	4	4	4	4	7	7	6
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></b>									
AGE AT DIAGNOSIS:									
<45	93.4	89.9	96.0	93.2	89.5	96.0	73.5 <sup>f</sup>	78.3 <sup>f</sup>	70.5 <sup>f</sup>
45-54	91.3	88.8	94.5	91.0	88.3	94.3	86.9 <sup>f</sup>	91.5 <sup>f</sup>	81.5 <sup>g</sup>
55-64	90.8	89.4	93.0	90.4	89.0	92.7	85.2 <sup>f</sup>	77.1 <sup>f</sup>	92.6 <sup>f</sup>
65-74	90.3	89.8	91.2	90.1	89.6	90.9	70.0 <sup>f</sup>	51.8 <sup>g</sup>	83.6 <sup>g</sup>
75+	84.7	84.4	84.9	84.4	84.2	84.3	45.7 <sup>g</sup>	37.4 <sup>g</sup>	53.0 <sup>g</sup>
Under 65	92.1	89.5	95.0	91.8	89.0	94.9	80.5	81.1 <sup>f</sup>	79.7
65 and over	88.5	88.2	88.8	88.2	88.0	88.5	60.6 <sup>f</sup>	46.8 <sup>g</sup>	70.4 <sup>g</sup>
STAGE:									
All Stages	91.1	89.1	93.5	90.8	88.7	93.3	74.4	69.9 <sup>f</sup>	77.4
Localized	98.5	98.1	99.0	98.3	97.9	98.8	94.2	89.1 <sup>f</sup>	95.5
Regional	65.2	61.8	70.5	65.3	61.8	70.9	44.7 <sup>f</sup>	55.0 <sup>g</sup>	31.8 <sup>g</sup>
Distant	15.3	15.3	15.6	14.7	15.0	14.3	26.3 <sup>f</sup>	16.2 <sup>f</sup>	-
Unstaged	77.0	74.7	79.5	76.0	73.9	78.4	59.3 <sup>g</sup>	-	-

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XVII-4  
MESOTHELIOMA

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	-	-	-	-	-	-
1970-1973 <sup>a</sup>	-	-	-	-	-	-	-	-	-
1975-1977 <sup>b</sup>	10.4	3.1	27.9 <sup>f</sup>	11.1	3.6	28.5 <sup>f</sup>	-	-	-
1978-1980 <sup>b</sup>	6.3	5.8	8.3	6.1	5.4	8.9	6.9 <sup>f</sup>	-	-
1981-1983 <sup>b</sup>	8.3	5.7	15.6	8.7	5.8	16.7	5.9 <sup>f</sup>	7.6 <sup>f</sup>	-
1984-1986 <sup>b</sup>	7.3	5.0	14.7	6.8	4.3	14.9	11.8 <sup>f</sup>	14.9 <sup>f</sup>	-
1987-1989 <sup>b</sup>	6.6	4.8	13.0	6.7	4.9	13.1	4.5	0.0	-
1990-1992 <sup>b</sup>	8.5	4.7	21.9	8.1	4.4	21.3	12.9 <sup>f</sup>	12.0 <sup>f</sup>	-
1993-1995 <sup>b</sup>	7.0	3.5	19.6	6.5	3.0	19.8	9.5 <sup>f</sup>	8.4 <sup>f</sup>	-
1996-2003 <sup>b</sup>	9.0	7.0	15.7	8.7	6.7 <sup>e</sup>	15.4	17.8 <sup>f</sup>	12.5 <sup>f</sup>	30.1 <sup>g</sup>
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	9.0	7.3	14.2	8.7	6.9	13.9	17.7	10.1	36.3
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	37.6	29.8 <sup>f</sup>	47.3 <sup>f</sup>	37.0 <sup>f</sup>	30.6 <sup>f</sup>	45.5 <sup>f</sup>	-	-	-
45-54	17.8	12.3	26.2 <sup>f</sup>	17.4	11.8	26.5 <sup>f</sup>	32.1 <sup>g</sup>	-	-
55-64	10.3	8.4	18.4	9.4	7.6	17.6 <sup>f</sup>	17.6 <sup>f</sup>	9.0 <sup>f</sup>	-
65-74	4.9	5.2	4.8	5.0	5.0	5.5	6.4	7.1 <sup>f</sup>	-
75+	4.2	4.2	4.4	4.1	4.0	4.7	4.4	6.2 <sup>f</sup>	-
Under 65	15.7	11.1	27.7	15.0	10.4	27.6	24.4 <sup>f</sup>	13.9 <sup>f</sup>	45.4 <sup>g</sup>
65 and over	4.7	4.8	4.5	4.6	4.6	4.9	5.4	6.6	0.0

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XVIII-5  
MYELOMA

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	12	13	10	-	-	-
1970-1973 <sup>a</sup>	-	-	-	19	20	17	-	-	-
1975-1977 <sup>b</sup>	25.9	25.5	26.3	25.4	25.1	25.8	30.7	31.6	29.7
1978-1980 <sup>b</sup>	27.0	25.6	28.5	26.1	25.6	26.6	32.5	26.9	37.9
1981-1983 <sup>b</sup>	28.7	26.8	30.7	28.5	26.7	30.3	29.6	30.3	28.8
1984-1986 <sup>b</sup>	28.5	29.0	27.9	27.4	27.3	27.4	32.1	33.4	30.6
1987-1989 <sup>b</sup>	28.5	30.1	26.8	28.2	30.5	25.8	30.8	30.3	31.3
1990-1992 <sup>b</sup>	30.4	31.6	29.1	29.6	30.7	28.3	35.5	39.7	31.5
1993-1995 <sup>b</sup>	32.6	33.3	31.8	31.6	32.7	30.4	35.3	34.0	36.0
1996-2003 <sup>b</sup>	33.6 <sup>e</sup>	35.7 <sup>e</sup>	31.2 <sup>e</sup>	33.6 <sup>e</sup>	35.8 <sup>e</sup>	31.0 <sup>e</sup>	32.2	34.9	30.0
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	33.6	35.1	31.7	33.0	34.9	30.8	33.7	34.4	32.9
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	55.3	56.4	53.3	56.4	58.3	52.7	49.9	49.5 <sup>f</sup>	50.5 <sup>f</sup>
45-54	50.5	51.0	49.8	51.7	53.1	49.3	44.3	41.2	47.3
55-64	39.4	40.5	37.8	40.7	41.5	39.5	35.0	38.0	31.6
65-74	31.6	31.9	31.4	31.5	31.1	32.0	31.2	33.1	29.2
75+	18.3	17.8	18.7	17.9	17.2	18.5	17.7	14.9	18.4
Under 65	45.3	46.4	43.7	46.4	47.8	44.1	40.5	40.8	40.1
65 and over	25.3	26.0	24.6	24.9	25.1	24.6	25.6	27.6	24.2

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XIX-5  
NON-HODGKIN LYMPHOMA

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE

	<u>All Races</u>			<u>Whites</u>			<u>Blacks</u>		
	<u>Total</u>	<u>Males</u>	<u>Females</u>	<u>Total</u>	<u>Males</u>	<u>Females</u>	<u>Total</u>	<u>Males</u>	<u>Females</u>
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	31	31	31	-	-	-
1970-1973 <sup>a</sup>	-	-	-	41	39	43	-	-	-
1975-1977 <sup>b</sup>	47.9	46.8	49.0	48.3	47.7	48.9	48.8	42.0	56.1 <sup>f</sup>
1978-1980 <sup>b</sup>	49.9	47.9	51.9	50.0	48.2	51.7	52.3	48.0	58.1 <sup>f</sup>
1981-1983 <sup>b</sup>	52.5	52.2	52.9	52.8	52.5	53.1	50.4	49.5	51.5
1984-1986 <sup>b</sup>	53.3	51.4	55.3	53.7	52.0	55.6	47.5	44.9	51.0
1987-1989 <sup>b</sup>	52.4	48.7	56.8	52.8	49.2	57.2	47.5	42.6	53.5
1990-1992 <sup>b</sup>	51.9	47.3	57.8	52.9	48.2	58.7	42.1	38.1	47.7
1993-1995 <sup>b</sup>	53.6	49.3	59.3	54.4	50.3	59.7	42.0	35.3	54.8
1996-2003 <sup>b</sup>	63.8 <sup>e</sup>	61.7 <sup>e</sup>	66.4 <sup>e</sup>	64.8 <sup>e</sup>	62.8 <sup>e</sup>	67.1 <sup>e</sup>	56.0	52.1	61.1
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	65.0	62.7	67.8	65.7	63.6	68.1	56.7	52.3	62.2
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	70.2	66.0	77.7	72.4	67.9	80.6	55.2	50.9	62.8
45-54	72.3	68.0	78.8	74.0	69.8	80.4	57.0	51.4	64.6
55-64	68.7	64.5	73.9	69.6	65.8	74.4	57.9	49.5	67.4
65-74	59.9	55.7	64.4	60.5	56.0	65.2	50.3	47.3	53.3
75+	47.9	46.4	48.9	48.3	46.8	49.3	42.5	45.8 <sup>f</sup>	40.2
Under 65	70.4	66.2	76.6	71.9	67.9	78.0	56.5	51.0	64.7
65 and over	54.4	51.8	56.5	54.8	52.1	57.1	47.4	46.9	47.5

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.



Table XX-5a  
 CANCER OF THE ORAL CAVITY AND PHARYNX (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	45	-	-	-	-	-
1970-1973 <sup>a</sup>	-	-	-	43	-	-	-	-	-
1975-1977 <sup>b</sup>	53.1	51.9	55.8	54.6	54.1	55.8	36.4	30.0	48.9
1978-1980 <sup>b</sup>	54.0	52.3	57.4	56.1	55.1	58.2	35.1	29.9	46.2
1981-1983 <sup>b</sup>	52.6	51.1	56.0	55.0	53.8	57.5	31.8	26.4	45.7
1984-1986 <sup>b</sup>	54.6	52.0	59.8	56.8	55.1	60.1	35.7	29.8	50.3
1987-1989 <sup>b</sup>	54.2	51.4	60.0	56.6	54.4	61.1	34.4	30.1	44.8
1990-1992 <sup>b</sup>	56.2	53.8	61.2	58.7	57.0	62.2	33.3	28.3	46.8
1993-1995 <sup>b</sup>	58.4	56.7	61.9	60.9	59.9	62.7	38.2	32.8	51.8
1996-2003 <sup>b</sup>	60.0 <sup>e</sup>	58.3 <sup>e</sup>	63.4 <sup>e</sup>	62.0 <sup>e</sup>	61.2 <sup>e</sup>	63.6 <sup>e</sup>	40.6	35.0	54.0
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	59.1	57.9	61.8	61.1	60.7	61.9	40.7	36.1	51.6
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	36,378	24,908	11,470	29,258	20,088	9,170	3,700	2,618	1,082
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	33	30	40	35	32	42	20	17	29
Regional	52	55	45	50	53	44	59	62	54
Distant	10	10	8	9	10	8	15	17	12
Unstaged	5	5	6	5	5	6	5	5	5
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	76.2	72.2	83.6	79.1	75.9	85.2	60.1	53.5	70.0
45-54	63.2	61.6	68.1	67.2	66.2	70.7	38.2	35.4	46.6
55-64	57.8	55.8	63.6	60.2	58.2	65.7	36.4	34.1	44.2
65-74	53.8	52.1	57.0	55.6	54.8	57.1	31.3	25.3	44.3
75+	46.6	45.9	47.2	47.5	47.4	47.6	34.7	25.1 <sup>f</sup>	45.7 <sup>f</sup>
Under 65	63.9	61.3	70.8	66.6	64.5	72.3	42.5	38.3	53.5
65 and over	51.0	50.0	52.6	52.4	52.2	52.7	32.5	25.3	45.7
STAGE:									
All Stages	59.1	57.6	62.6	61.0	60.2	62.8	40.1	35.5	51.3
Localized	81.8	81.0	82.9	82.2	82.2	82.4	72.2	64.3	82.3
Regional	52.1	52.2	52.0	53.9	54.6	51.8	34.5	32.1	41.2
Distant	26.5	25.2	29.9	27.2	25.7	30.9	21.0	21.3	20.8
Unstaged	46.2	45.2	47.9	45.3	45.8	44.0	34.0	28.4 <sup>f</sup>	44.8 <sup>f</sup>

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XX-6b  
 CANCER OF THE ORAL CAVITY AND PHARYNX FOR SELECTED SUBSITES (Invasive)

SURVIVAL RATES<sup>a</sup>

By Year of Diagnosis

All Races, Males and Females

Year of Diagnosis

	1975- 1979	1980- 1984	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Relative Survival Rates (SEER <sup>b</sup> )																					
<u>Tongue Cancer</u>																					
1-year	75.4	74.4	80.7	76.7	78.4	77.3	75.9	80.3	82.4	77.3	82.0	82.2	80.4	79.9	82.5	80.1	82.2	85.5	82.2	81.9	85.2
2-year	55.5	58.1	63.8	59.8	61.3	59.4	59.7	64.6	66.9	60.7	65.8	68.8	65.9	67.1	71.3	66.2	68.8	72.1	71.3	69.2	
3-year	48.1	51.4	57.5	56.3	55.4	51.1	54.2	58.5	58.8	51.1	57.6	63.3	59.4	61.2	65.5	59.6	61.0	66.9	64.9		
4-year	44.3	48.1	53.1	52.9	49.8	46.8	50.1	55.8	53.5	47.3	54.7	59.0	57.4	57.5	62.7	56.0	58.9	64.2			
5-year	41.1	45.5	49.8	51.8	46.4	44.4	47.5	52.9	52.8	44.5	52.3	55.2	55.0	55.9	59.0	53.4	56.2				
6-year	39.4	42.6	48.1	48.1	46.0	41.6	44.9	50.7	49.2	43.1	50.5	53.1	51.6	53.7	57.6	52.9					
7-year	38.4	40.1	45.8	46.2	43.9	35.5	43.4	48.0	47.4	41.5	47.8	52.6	49.8	52.6	56.9						
8-year	37.0	38.5	45.1	44.7	42.3	32.4	40.9	45.9	46.7	40.1	45.7	49.1	47.8	51.1							
9-year	35.9	35.8	42.6	43.8	41.2	31.0	38.9	42.8	45.1	36.4	43.4	47.2	46.1								
10-year	34.2	34.4	42.0	42.5	40.1	30.9	37.1	40.9	42.4	34.1	43.1	46.0									
<u>Lip Cancer</u>																					
1-year	99.3	98.2	99.2	99.4	99.9	100.0	97.8	99.0	100.0	100.0	99.3	100.0	99.9	98.2	100.0	99.3	97.4	97.8	94.8	99.6	99.1
2-year	97.5	96.6	97.4	97.1	98.4	97.8	97.5	97.8	98.6	98.5	98.7	100.0	99.5	94.0	96.8	97.9	95.1	96.1	93.7	99.6	
3-year	97.1	94.4	95.0	95.7	98.4	96.3	96.6	96.3	98.6	97.0	98.6	100.0	98.7	92.6	94.6	95.5	93.5	94.9	93.7		
4-year	95.8	93.3	95.0	95.7	98.4	94.9	95.8	96.3	97.8	95.3	98.6	98.0	95.8	91.7	93.0	93.7	91.6	91.7			
5-year	94.4	91.2	95.0	95.2	97.6	93.0	93.9	95.1	96.0	94.5	96.5	97.4	94.7	89.4	90.8	91.3	90.1				
6-year	92.7	89.2	95.0	92.8	96.8	91.3	93.5	93.3	96.0	91.0	95.9	97.0	94.7	88.5	89.3	90.0					
7-year	91.5	88.1	93.8	91.5	95.4	88.6	92.8	92.6	95.8	88.2	94.3	97.0	94.7	88.0	88.4						
8-year	90.4	88.1	93.0	89.1	94.1	86.7	92.8	92.3	95.1	85.9	91.5	95.8	90.8	85.4							
9-year	88.4	87.5	93.0	87.2	93.8	86.7	90.1	89.9	93.0	84.8	90.2	93.9	86.3								
10-year	86.7	86.4	93.0	86.0	93.3	86.7	88.2	89.1	91.0	83.2	88.5	90.8									
<u>Oropharynx and Tonsil Cancer</u>																					
1-year	71.4	72.4	75.3	71.4	71.7	76.2	75.1	76.8	76.8	71.4	77.7	74.5	81.1	80.4	81.8	81.2	87.5	82.8	84.1	85.7	82.9
2-year	54.2	53.4	57.3	52.1	55.3	57.5	61.7	60.5	63.0	58.5	64.9	63.8	70.2	66.7	67.5	66.7	75.4	67.6	72.6	76.4	
3-year	44.8	45.2	46.4	46.0	43.4	44.1	52.2	51.8	57.7	49.9	55.8	57.7	63.0	60.4	62.4	60.1	67.8	62.6	67.0		
4-year	39.4	40.1	44.0	42.5	41.8	37.8	45.5	48.1	53.3	45.0	49.9	53.4	58.9	54.1	57.0	55.1	63.5	57.9			
5-year	36.3	36.2	37.6	39.0	39.1	34.5	43.6	43.4	46.7	41.6	46.4	50.1	54.8	53.1	52.7	53.3	61.0				
6-year	32.9	33.0	34.5	37.4	35.0	32.2	40.1	43.1	41.8	40.6	44.5	47.0	51.4	48.7	49.6	52.3					
7-year	31.1	30.6	31.6	34.3	32.3	30.1	37.5	41.1	40.2	39.7	43.5	46.6	48.1	44.6	48.9						
8-year	27.5	29.1	30.0	32.3	29.3	29.6	37.0	39.7	37.7	38.7	41.6	43.2	47.3	43.5							
9-year	24.8	26.9	27.6	29.9	27.1	29.3	35.9	35.5	35.9	37.0	39.0	42.1	46.2								
10-year	23.6	24.5	24.1	28.8	26.5	25.2	34.6	35.4	34.1	37.0	35.8	41.2									

<sup>a</sup> Survival rates are relative rates expressed as percents.<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

Table XXI-5  
OVARY CANCER (Invasive)

	SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE								
	All Races, Females			White Females			Black Females		
	All	<65	65+	All	<65	65+	All	<65	65+
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	32	-	-	32	-	-
1970-1973 <sup>a</sup>	-	-	-	36	-	-	32	-	-
1975-1977 <sup>b</sup>	37.2	44.4	21.9	36.5	43.7	21.6	43.1	49.2	25.5 <sup>f</sup>
1978-1980 <sup>b</sup>	38.9	47.4	22.6	38.0	46.5	22.8	40.3	49.7	13.0
1981-1983 <sup>b</sup>	40.7	50.6	24.5	40.3	50.5	24.5	39.3	46.3	23.4 <sup>f</sup>
1984-1986 <sup>b</sup>	39.8	49.6	24.8	38.9	48.7	24.6	40.5	52.4	21.3
1987-1989 <sup>b</sup>	39.9	51.3	24.7	39.9	51.4	25.1	35.3	47.6	17.9
1990-1992 <sup>b</sup>	42.5	55.6	25.6	42.5	56.2	25.6	37.8	49.8	17.7
1993-1995 <sup>b</sup>	43.5	55.9	28.0	42.7	55.6	27.5	42.8	54.7	27.5
1996-2003 <sup>b</sup>	45.0 <sup>e</sup>	56.3 <sup>e</sup>	29.1 <sup>e</sup>	44.7 <sup>e</sup>	56.5 <sup>e</sup>	29.1 <sup>e</sup>	37.5	46.7	21.4
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	44.9	56.7	27.6	44.5	56.9	27.5	37.9	46.0	23.1
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	26,953	14,532	12,421	22,985	12,003	10,982	1,867	1,083	784
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	19	27	9	18	26	9	17	24	8
Regional	7	8	6	7	8	5	7	7	7
Distant	68	62	75	69	62	76	67	63	72
Unstaged	7	4	10	7	4	10	9	6	13
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	72.2	-	-	72.9	-	-	67.2	-	-
45-54	55.8	-	-	56.4	-	-	43.1	-	-
55-64	45.3	-	-	45.8	-	-	33.4	-	-
65-74	34.8	-	-	34.9	-	-	23.9	-	-
75+	21.4	-	-	21.7	-	-	17.2	-	-
Under 65	56.1	-	-	56.3	-	-	47.9	-	-
65 and over	28.7	-	-	28.8	-	-	21.1	-	-
STAGE:									
All Stages	44.9	56.1	28.7	44.6	56.3	28.8	38.2	47.9	21.1
Localized	92.4	92.8	91.6	92.6	93.2	90.9	91.2	92.1	87.4 <sup>f</sup>
Regional	71.4	76.6	59.8	72.2	78.3	59.7	58.7 <sup>f</sup>	62.7 <sup>f</sup>	49.2 <sup>g</sup>
Distant	29.8	38.1	20.2	30.0	38.6	20.6	22.8	29.4	12.9
Unstaged	24.8	45.5	11.2	24.5	44.8	12.3	24.0	47.1 <sup>f</sup>	0.0

Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XXII-5  
PANCREAS CANCER (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	1	1	2	1	0	3
1970-1973 <sup>a</sup>	-	-	-	2	2	2	2	0	3
1975-1977 <sup>b</sup>	2.4	2.6	2.2	2.5	2.7	2.3	2.3	2.7	2.0
1978-1980 <sup>b</sup>	3.0	2.8	3.2	2.7	2.6	2.7	5.9	4.3	7.4
1981-1983 <sup>b</sup>	3.0	2.6	3.4	2.8	2.3	3.3	3.7	4.0	3.3
1984-1986 <sup>b</sup>	3.0	2.4	3.5	2.7	2.2	3.1	4.9	4.2	5.4
1987-1989 <sup>b</sup>	3.8	3.5	4.1	3.4	3.2	3.5	5.7	5.1	6.1
1990-1992 <sup>b</sup>	4.5	4.2	4.7	4.6	4.3	4.9	3.7	3.2	4.0
1993-1995 <sup>b</sup>	4.2	3.9	4.6	4.2	3.8	4.6	3.7	3.5	3.9
1996-2003 <sup>b</sup>	5.0 <sup>e</sup>	5.0 <sup>e</sup>	5.0 <sup>e</sup>	4.9 <sup>e</sup>	5.3 <sup>e</sup>	4.4 <sup>e</sup>	4.6 <sup>e</sup>	3.2	5.8 <sup>e</sup>
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	5.4	5.5	5.3	5.2	5.5	5.0	5.6	4.2	6.5
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	37,749	18,311	19,438	30,639	14,982	15,657	4,234	1,918	2,316
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	7	6	8	7	6	8	8	6	9
Regional	26	25	26	26	25	26	24	23	25
Distant	52	55	49	52	55	48	54	59	50
Unstaged	15	13	17	15	13	17	14	12	15
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	19.5	14.9	25.4	19.1	15.2	24.0	18.6	13.9	24.7 <sup>f</sup>
45-54	7.6	6.9	8.8	7.7	7.7	7.9	6.0	3.0	11.1
55-64	5.4	4.7	6.4	5.4	4.7	6.4	4.3	3.2	5.3
65-74	3.9	3.8	4.0	4.0	4.1	3.7	3.3	2.2	4.0
75+	2.5	2.8	2.3	2.4	2.7	2.2	1.9	-	2.6
Under 65	7.8	6.6	9.4	7.7	6.9	8.9	6.5	4.4	9.2
65 and over	3.2	3.4	3.0	3.2	3.6	2.9	2.7	1.6	3.3
STAGE:									
All Stages	5.0	4.9	5.1	4.9	5.1	4.7	4.5	3.2	5.6
Localized	20.3	18.9	21.2	20.7	19.8	21.2	14.7	9.8	16.8
Regional	8.0	8.2	7.9	8.1	9.0	7.3	6.9	4.4	8.5
Distant	1.7	2.0	1.5	1.6	1.8	1.3	1.9	2.3	1.4
Unstaged	4.1	4.6	3.7	3.6	4.5	2.9	4.4	2.0	6.7

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Rates are based on follow-up of patients into 2004.  
<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.  
<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).  
<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).  
<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.  
<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.  
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XXIII-5  
PROSTATE CANCER (Invasive)

SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE

	All Races, Males			White Males			Black Males		
	All	<65	65+	All	<65	65+	All	<65	65+
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	50	-	-	35	-	-
1970-1973 <sup>a</sup>	-	-	-	63	-	-	55	-	-
1975-1977 <sup>b</sup>	68.9	73.4	67.2	69.8	75.2	67.8	61.3	61.9	61.0
1978-1980 <sup>b</sup>	72.0	75.7	70.6	73.2	77.2	71.8	62.8	65.3	61.5
1981-1983 <sup>b</sup>	73.8	76.4	72.8	75.0	78.0	73.9	63.7	65.4	62.9
1984-1986 <sup>b</sup>	76.1	77.4	75.6	77.3	79.1	76.8	66.3	67.3	65.8
1987-1989 <sup>b</sup>	83.9	83.3	84.0	85.4	84.8	85.6	72.2	72.7	72.0
1990-1992 <sup>b</sup>	94.2	93.4	94.4	95.3	94.4	95.5	85.5	86.9	84.8
1993-1995 <sup>b</sup>	95.4	95.8	95.2	96.1	96.5	96.0	91.4	92.9	90.3
1996-2003 <sup>b</sup>	98.5 <sup>e</sup>	99.0 <sup>e</sup>	98.6 <sup>e</sup>	99.0 <sup>e</sup>	99.4 <sup>e</sup>	99.1 <sup>e</sup>	95.3 <sup>e</sup>	97.8 <sup>e</sup>	93.6 <sup>e</sup>
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	99.4	99.0	99.6	99.8	99.4	99.7	95.8	97.6	93.9
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	277,571	99,627	177,944	221,200	77,891	143,309	34,802	15,983	18,819
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized/Regional	91	95	89	92	95	90	89	93	85
Distant	5	3	5	4	3	5	6	5	8
Unstaged	4	2	6	4	2	5	5	3	7
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	93.6	-	-	93.2	-	-	94.4	-	-
45-54	97.3	-	-	97.5	-	-	96.0	-	-
55-64	99.3	-	-	99.6	-	-	97.8	-	-
65-74	100.0	-	-	100.0	-	-	96.2	-	-
75+	94.8	-	-	95.2	-	-	85.7	-	-
Under 65	98.7	-	-	99.1	-	-	97.2	-	-
65 and over	98.7	-	-	99.2	-	-	93.2	-	-
STAGE:									
All Stages	98.4	98.7	98.7	98.9	99.1	99.2	94.9	97.2	93.2
Localized/Regional	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Distant	31.9	32.3	31.8	30.7	32.4	30.2	29.8	27.7	31.2
Unstaged	79.1	88.3	76.5	78.2	89.1	75.3	72.6	82.8	67.9

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Rates are based on follow-up of patients into 2004.  
<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.  
<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).  
<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).  
<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.  
<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.  
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XXIV-5  
STOMACH CANCER (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	11	10	13	8	5	14
1970-1973 <sup>a</sup>	-	-	-	13	12	14	13	15	10
1975-1977 <sup>b</sup>	15.9	15.0	17.1	14.8	13.7	16.4	16.3	16.4	16.1
1978-1980 <sup>b</sup>	16.8	14.9	19.9	16.2	14.4	19.1	16.9	16.0	18.6
1981-1983 <sup>b</sup>	18.0	17.1	19.5	16.9	16.0	18.3	17.2	16.8	17.7
1984-1986 <sup>b</sup>	18.4	16.2	21.8	17.6	15.1	21.6	20.0	17.5	23.4
1987-1989 <sup>b</sup>	20.7	17.6	26.0	19.1	16.0	24.5	20.0	17.2	24.5
1990-1992 <sup>b</sup>	21.6	18.6	26.5	19.3	16.4	24.0	24.1	23.1	25.3
1993-1995 <sup>b</sup>	21.7	20.5	23.9	20.7	19.3	23.1	19.8	17.6	23.0
1996-2003 <sup>b</sup>	24.1 <sup>e</sup>	22.7 <sup>e</sup>	26.5 <sup>e</sup>	22.2 <sup>e</sup>	20.4 <sup>e</sup>	25.4 <sup>e</sup>	24.2 <sup>e</sup>	22.1	26.8 <sup>e</sup>
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	24.6	23.0	27.3	22.8	21.1	25.7	24.0	22.1	26.0
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	28,907	17,500	11,407	20,361	12,623	7,738	3,653	2,039	1,614
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	24	23	25	23	22	25	24	22	27
Regional	30	31	28	29	31	27	28	30	27
Distant	35	36	33	36	37	34	35	37	31
Unstaged	12	10	14	12	10	15	13	10	16
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	28.3	26.6	30.4	27.0	24.8	29.8	33.2	29.1	38.6
45-54	26.9	24.3	32.0	23.8	21.3	29.3	30.4	25.7	38.4
55-64	24.7	23.2	27.9	22.4	21.1	25.8	23.0	19.3	30.3
65-74	24.7	22.5	28.7	22.5	19.9	27.4	22.8	21.2	24.3
75+	21.0	19.8	22.4	20.1	19.4	20.9	14.6	10.4	17.3
Under 65	26.1	24.2	30.0	23.7	21.8	28.0	28.3	23.8	36.1
65 and over	22.9	21.3	25.1	21.3	19.7	23.6	19.1	17.2	20.6
STAGE:									
All Stages	24.3	22.6	26.9	22.3	20.6	25.1	23.6	20.9	27.1
Localized	61.1	58.4	65.0	58.2	54.9	63.2	56.8	53.8	59.7
Regional	23.7	22.8	25.1	21.3	20.7	22.6	25.6	24.3	27.3
Distant	3.4	3.2	3.8	3.2	3.0	3.5	2.7	2.0	3.6
Unstaged	14.5	12.4	17.2	13.9	11.7	16.6	12.6	8.7	16.0

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Rates are based on follow-up of patients into 2004.  
<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.  
<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).  
<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).  
<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.  
<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.  
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XXV-5  
TESTIS CANCER (Invasive)

SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE

	All Races, Males			White Males			Black Males		
	All	<50	50+	All	<50	50+	All	<50	50+
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	63	-	-	-	-	-
1970-1973 <sup>a</sup>	-	-	-	72	-	-	-	-	-
1975-1977 <sup>b</sup>	82.8	83.4	78.4	82.7	83.3	78.1	82.0 <sup>f</sup>	85.0 <sup>f</sup>	-
1978-1980 <sup>b</sup>	89.0	89.4	84.2	89.3	89.7	85.1	72.7 <sup>f</sup>	77.1 <sup>f</sup>	-
1981-1983 <sup>b</sup>	92.3	92.7	87.0	92.5	92.9	87.2	87.5 <sup>f</sup>	84.7 <sup>f</sup>	-
1984-1986 <sup>b</sup>	92.8	93.6	81.9	93.1	94.0	82.2	87.0 <sup>f</sup>	89.4 <sup>f</sup>	-
1987-1989 <sup>b</sup>	95.1	95.0	95.5	95.4	95.4	95.2	88.4 <sup>f</sup>	87.8 <sup>f</sup>	-
1990-1992 <sup>b</sup>	95.8	95.8	94.4	96.2	96.1	95.4	83.6 <sup>f</sup>	88.6 <sup>f</sup>	-
1993-1995 <sup>b</sup>	95.7	96.2	86.5	95.9	96.5	87.5	88.2	89.4	-
1996-2003 <sup>b</sup>	96.0 <sup>e</sup>	96.4 <sup>e</sup>	89.7 <sup>e</sup>	96.3 <sup>e</sup>	96.7 <sup>e</sup>	90.4 <sup>e</sup>	87.5	89.0	-
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	95.9	96.2	92.4	96.1	96.4	92.5	90.8	93.1	-
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	11,757	10,756	1,001	10,802	9,885	917	343	312	31
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	70	70	67	71	71	68	59	61	48
Regional	17	17	18	17	17	17	22	22	23
Distant	11	11	12	11	10	12	16	16	19
Unstaged	1	1	3	1	1	3	2	2	10
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	95.7	-	-	96.0	-	-	91.2	-	-
45-54	95.7	-	-	96.4	-	-	82.7 <sup>f</sup>	-	-
55-64	90.5	-	-	91.0	-	-	-	-	-
65-74	75.0 <sup>f</sup>	-	-	75.6 <sup>f</sup>	-	-	-	-	-
75+	64.4 <sup>g</sup>	-	-	68.5 <sup>g</sup>	-	-	-	-	-
Under 65	95.6	-	-	96.0	-	-	89.0	-	-
65 and over	74.0 <sup>f</sup>	-	-	75.7 <sup>f</sup>	-	-	-	-	-
STAGE:									
All Stages	95.4	95.7	91.4	95.7	96.0	92.2	88.2	90.8	49.6 <sup>g</sup>
Localized	99.3	99.4	98.2	99.4	99.5	98.4	98.1	99.9	-
Regional	95.8	96.0	92.0	96.0	96.1	93.5	90.8	94.2	-
Distant	70.0	71.3	55.8 <sup>f</sup>	71.3	72.7	56.2 <sup>f</sup>	51.6 <sup>f</sup>	52.0 <sup>f</sup>	-
Unstaged	87.4	91.8	66.8 <sup>g</sup>	88.8	92.3	70.9 <sup>g</sup>	-	-	-

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Rates are based on follow-up of patients into 2004.  
<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.  
<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).  
<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).  
<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.  
<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.  
- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XXVI-5  
THYROID CANCER (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<u>5-YR RELATIVE SURVIVAL RATES</u>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	83	75	87	-	-	-
1970-1973 <sup>a</sup>	-	-	-	86	82	87	-	-	-
1975-1977 <sup>b</sup>	93.2	92.6	93.4	93.0	92.3	93.1	90.6	83.9 <sup>g</sup>	91.7
1978-1980 <sup>b</sup>	93.2	88.5	94.6	92.7	88.8	93.8	90.5	68.8 <sup>g</sup>	95.7
1981-1983 <sup>b</sup>	94.4	93.0	94.8	93.9	91.9	94.5	96.7	100.0	93.8
1984-1986 <sup>b</sup>	93.9	90.9	94.8	93.9	90.6	94.8	90.0	86.1 <sup>f</sup>	90.8
1987-1989 <sup>b</sup>	95.1	92.4	95.9	94.9	92.4	95.6	92.5	90.7 <sup>f</sup>	92.6
1990-1992 <sup>b</sup>	95.0	91.3	96.1	95.6	92.5	96.6	86.9	84.8 <sup>f</sup>	87.5
1993-1995 <sup>b</sup>	96.0	92.5	97.0	96.0	92.3	97.2	93.4	88.3 <sup>f</sup>	94.4
1996-2003 <sup>b</sup>	96.8 <sup>e</sup>	93.8	97.7 <sup>e</sup>	97.2 <sup>e</sup>	94.4	98.0 <sup>e</sup>	94.4	89.4	95.3
<u>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></u>									
YEAR OF DIAGNOSIS:									
1996-2003	97.2	94.8	97.9	97.3	95.1	97.9	95.1	90.3	96.1
<u>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></u>									
All Stages									
Number of cases	30,636	7,116	23,520	25,217	6,059	19,158	1,753	326	1,427
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	59	49	61	59	49	62	63	55	65
Regional	34	40	32	34	40	32	27	32	26
Distant	5	9	4	5	8	4	7	11	6
Unstaged	3	2	3	2	2	3	3	3	2
<u>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></u>									
AGE AT DIAGNOSIS:									
<45	99.3	97.8	99.6	99.3	98.3	99.6	97.7	89.3	99.1
45-54	97.8	95.1	98.6	98.1	95.4	99.0	93.8	86.7	95.1
55-64	94.5	90.7	95.9	94.8	90.8	96.4	90.1	84.3 <sup>f</sup>	91.0
65-74	91.3	87.5	92.8	91.6	88.3	92.9	91.9	91.3 <sup>g</sup>	91.1
75+	77.9	77.5	78.0	79.0	77.4	79.5	69.1 <sup>g</sup>	-	62.2 <sup>g</sup>
Under 65	98.2	95.6	98.9	98.4	96.0	99.1	95.3	88.1	96.8
65 and over	86.8	84.6	87.6	87.2	85.0	88.1	84.9	93.6 <sup>f</sup>	82.7 <sup>f</sup>
STAGE:									
All Stages	96.7	93.9	97.5	97.0	94.3	97.8	94.6	89.9	95.4
Localized	99.7	99.3	99.8	99.8	99.4	99.8	98.1	94.6	98.6
Regional	96.9	95.6	97.3	97.1	95.9	97.5	96.7	93.7	97.0
Distant	56.0	54.9	56.5	56.1	54.5	57.2	48.6 <sup>f</sup>	47.2 <sup>g</sup>	49.0 <sup>f</sup>
Unstaged	89.3	84.0	90.7	88.4	82.0	90.3	84.3 <sup>f</sup>	-	84.6 <sup>f</sup>

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.  
<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).  
Rates are based on follow-up of patients into 2004.  
<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.  
<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).  
<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).  
<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.  
<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.  
- Statistic could not be calculated due to fewer than 16 cases during the time period.



Table XXVII-5  
URINARY BLADDER CANCER (Invasive and *In Situ*)

## SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

	All Races			Whites			Blacks		
	Total	Males	Females	Total	Males	Females	Total	Males	Females
<b>5-YR RELATIVE SURVIVAL RATES</b>									
YEAR OF DIAGNOSIS:									
1960-1963 <sup>a</sup>	-	-	-	53	53	53	24	24	24
1970-1973 <sup>a</sup>	-	-	-	61	61	60	36	38	27
1975-1977 <sup>b</sup>	73.5	75.0	69.6	74.5	75.6	71.5	50.6	56.8	38.8 <sup>f</sup>
1978-1980 <sup>b</sup>	76.0	77.2	72.7	76.9	77.6	74.8	55.6	64.3	40.8 <sup>f</sup>
1981-1983 <sup>b</sup>	78.6	79.9	75.0	79.3	80.4	76.4	60.3	65.7	48.4 <sup>f</sup>
1984-1986 <sup>b</sup>	78.2	79.5	74.6	78.7	79.9	75.5	60.8	63.7	54.2 <sup>f</sup>
1987-1989 <sup>b</sup>	80.6	82.8	74.1	81.4	83.4	75.4	63.3	68.0	54.0 <sup>f</sup>
1990-1992 <sup>b</sup>	80.9	83.3	74.1	81.9	84.1	75.3	64.7	67.6	59.9
1993-1995 <sup>b</sup>	81.4	83.0	76.9	82.2	83.4	78.8	61.8	69.0	46.8
1996-2003 <sup>b</sup>	80.6 <sup>e</sup>	81.6 <sup>e</sup>	77.8 <sup>e</sup>	81.3 <sup>e</sup>	82.1 <sup>e</sup>	79.0 <sup>e</sup>	65.0 <sup>e</sup>	68.3 <sup>e</sup>	57.9 <sup>e</sup>
<b>5-YR PERIOD SURVIVAL RATES<sup>cd</sup></b>									
YEAR OF DIAGNOSIS:									
1996-2003	79.1	80.5	75.1	79.8	80.8	76.7	64.4	69.8	54.9
<b>STAGE DISTRIBUTION (%) 1996-2003<sup>c</sup></b>									
All Stages									
Number of cases	65,633	48,935	16,698	59,375	44,558	14,817	3,062	1,957	1,105
Percent	100%	100%	100%	100%	100%	100%	100%	100%	100%
Localized	75	76	71	75	77	72	60	64	51
Regional	19	18	21	18	18	20	28	25	34
Distant	4	3	5	3	3	5	6	5	9
Unstaged	3	3	4	3	3	4	6	6	5
<b>5-YR RELATIVE SURVIVAL RATES, 1996-2003<sup>c</sup></b>									
AGE AT DIAGNOSIS:									
<45	91.2	91.5	90.5	92.2	92.4	91.8	80.7	82.7	76.9 <sup>f</sup>
45-54	85.2	85.8	83.5	86.1	86.5	85.0	70.2	73.4	59.4 <sup>f</sup>
55-64	84.8	85.3	83.2	85.5	85.8	84.3	73.1	76.4	63.6
65-74	79.8	80.9	76.5	80.4	81.1	78.1	60.5	65.8	51.3
75+	71.0	73.3	65.9	71.8	73.9	66.9	51.3	52.0	47.8
Under 65	85.8	86.2	84.3	86.5	86.8	85.6	73.4	76.5	64.7
65 and over	75.7	77.6	70.7	76.4	78.0	72.0	56.1	59.9	50.4
STAGE:									
All Stages	79.5	80.9	75.3	80.2	81.4	76.6	63.9	68.2	55.5
Localized	92.1	92.4	91.3	92.3	92.5	91.7	84.3	85.7	80.0
Regional	44.6	46.6	39.5	45.3	47.1	40.3	37.6	40.6	32.4
Distant	6.4	6.1	6.6	6.1	6.4	5.5	9.0	2.9	15.0
Unstaged	59.3	63.6	47.7	59.8	63.6	49.4	42.5 <sup>f</sup>	49.9 <sup>f</sup>	25.8 <sup>f</sup>

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta).

Rates are based on follow-up of patients into 2004.

<sup>c</sup> Rates are from the SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>d</sup> Period survival provides a more up-to-date estimate of survival by piecing together the most recent conditional survival estimates from several cohorts. It is computed here using three calendar year blocks (2001-2003: 0-1 year survival), (2000-2002: 1-2 year survival), (1999-2001: 2-3 year survival), (1998-2000: 3-4 year survival), (1997-1999: 4-5 years survival).

<sup>e</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant ( $p < .05$ ).

<sup>f</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>g</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Table XXVIII-9

**CHILDHOOD CANCER**  
SEER Incidence, U.S. Death and 5-Year Relative Survival Rates  
For Top Cancer Sites<sup>f</sup> By 5-Year Age Groups  
All Races, Males and Females

Age/Site	SEER Incidence <sup>a</sup>					US Mortality <sup>b</sup>					Survival <sup>a</sup>	
	2000-2004 Num Cases	2000-2004 Rate	1975-2004 APC	1975-1989 APC	1990-2004 APC	2000-2004 Num Deaths	2000-2004 Rate	1975-2004 APC	1975-1989 APC	1990-2004 APC	1975-1977	1996-2003
<b>Ages 0-4</b>												
All Sites	5,638	21.2	0.7*	1.3*	0.3 <sup>®</sup>	2,414	2.5	-2.8*	-2.8*	-2.2*	57.3	80.2 <sup>c</sup>
Soft tissue	439	1.6	0.7	0.9	1.8	121	0.1	-2.0*	-0.1	-1.3	61.1 <sup>d</sup>	70.9
Kidney and Renal pelvis	475	1.8	0.0	0.6	-0.5	89	0.1	-3.8*	-5.9*	-0.2 <sup>#</sup>	72.2	91.6 <sup>c</sup>
Eye and Orbit	347	1.3	0.5	1.1	-1.4	31	0.0	-	-	-	87.1 <sup>d</sup>	95.3 <sup>c</sup>
Brain and Other nervous	1,052	4.0	1.3*	3.5*	0.4 <sup>#</sup>	609	0.6	-1.3*	-1.4*	-1.9*	52.4	70.1 <sup>c</sup>
Other endocrine	360	1.3	-	-	-	403	0.4	-	-	-	33.8 <sup>d</sup>	65.7 <sup>c</sup>
Leukemia	2,118	8.0	0.8*	1.1*	1.0	786	0.8	-3.2*	-4.0*	-2.5* <sup>#</sup>	55.4	84.9 <sup>c</sup>
Acute lymphocytic	1,699	6.4	0.8*	1.6*	0.8	273	0.3	-4.5*	-5.8*	-2.0* <sup>#</sup>	63.1	90.4 <sup>c</sup>
<b>Ages 5-9</b>												
All Sites	3,067	11.2	0.2	1.2*	-0.1 <sup>®</sup>	2,561	2.6	-2.8*	-3.3*	-1.7* <sup>#</sup>	58.5	78.3 <sup>c</sup>
Brain and Other nervous	866	3.2	0.4	1.4	-0.5	899	0.9	-0.7*	-0.6	-0.6	58.0	72.9 <sup>c</sup>
Leukemia	1,080	3.9	0.5	1.9*	-0.4 <sup>®</sup>	755	0.8	-4.9*	-5.6*	-3.7* <sup>#</sup>	52.3	81.9 <sup>c</sup>
Acute lymphocytic	898	3.3	0.8*	2.6*	0.1 <sup>®</sup>	414	0.4	-5.6*	-6.6*	-3.6* <sup>#</sup>	55.6	85.0 <sup>c</sup>
<b>Ages 10-14</b>												
All Sites	3,579	12.6	0.7*	1.2*	0.5	2,628	2.5	-2.2*	-2.6*	-1.4* <sup>#</sup>	58.9	79.9 <sup>c</sup>
Bone and Joint	369	1.3	0.1	2.1	-1.3 <sup>#</sup>	316	0.3	-1.4*	-3.4*	0.7 <sup>#</sup>	52.8 <sup>d</sup>	68.2 <sup>c</sup>
Brain and Other nervous	740	2.6	1.2*	1.0	-0.2	715	0.7	-1.2*	-1.9*	-0.5	59.5	80.7 <sup>c</sup>
Hodgkin lymphoma	316	1.1	-1.1*	-0.9	-2.2	23	0.0	-	-	-	78.7	95.7 <sup>c</sup>
Leukemia	809	2.9	0.5	2.7	1.1	853	0.8	-3.0*	-3.2*	-2.8*	35.2	70.3 <sup>c</sup>
Acute lymphocytic	564	2.0	1.0*	3.9*	1.5	420	0.4	-3.4*	-2.8*	-3.1*	43.6 <sup>d</sup>	80.7 <sup>c</sup>
<b>Ages 15-19</b>												
All Sites	5,649	21.0	0.6*	1.1*	0.3	3,621	3.5	-1.9*	-2.4*	-1.6* <sup>#</sup>	68.0	80.5 <sup>c</sup>
Bone and Joint	410	1.5	0.3	1.4	-0.3	511	0.5	-1.4*	-2.8*	0.3 <sup>#</sup>	51.0 <sup>d</sup>	65.7 <sup>c</sup>
Melanoma of the skin	467	1.7	1.6*	1.8	1.0	44	0.0	-	-	-	76.2 <sup>d</sup>	98.1 <sup>c</sup>
Testis(males)	475	3.4	1.4*	1.5	1.1	46	0.1	-	-	-	66.0 <sup>d</sup>	92.6 <sup>c</sup>
Brain and Other nervous	550	2.0	0.3	1.4	-1.1	545	0.5	-1.1*	-1.2*	-1.2*	65.0	80.9 <sup>c</sup>
Thyroid	481	1.8	1.3*	1.1	1.9	-	-	-	-	-	100.0	97.5
Hodgkin lymphoma	779	2.9	-0.8*	0.5	-1.6* <sup>#</sup>	106	0.1	-4.4*	-3.1*	-4.8*	88.9	95.0 <sup>c</sup>
Non-Hodgkin lymphoma	488	1.8	1.8*	3.5*	1.3	274	0.3	-2.7*	-2.6*	-3.3*	46.1 <sup>d</sup>	77.6 <sup>c</sup>
Leukemia	792	3.0	0.9*	0.0	1.8	1,097	1.1	-2.1*	-2.3*	-2.6*	24.4	51.7 <sup>c</sup>
Acute lymphocytic	458	1.7	1.2*	2.2	2.6*	484	0.5	-2.0*	-1.6*	-2.4*	29.5 <sup>d</sup>	55.3 <sup>c</sup>

The APC is the Annual Percent Change over the time interval.

Note: Incidence and death rates are per 100,000 and are age-adjusted (as appropriate) to the 2000 US Std Population (19 age groups - Census P25-1130). Survival rates are expressed as percents.

<sup>a</sup> Incidence data used in calculating the rates are from the 17 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey).

Incidence data used in calculating the trends and survival estimates are from the 9 SEER areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta).

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> The difference in rates between 1975-1977 and 1996-2003 is statistically significant (p<.05).

<sup>d</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>e</sup> The standard error of the survival rate is greater than 10 percentage points.

<sup>f</sup> Sites were chosen based on more than 100 SEER incident cases between 2000-2004.

\* The APC is significantly different from zero (p<.05).

# The APC for 1990-2004 is significantly different from the APC for 1975-1989 (p<.05).

® The APC for 1990-2004 is significantly different from the APC for 1975-1989 (p<.10).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table XXIX-6

5-YEAR RELATIVE SURVIVAL RATES, 1996-2003<sup>a</sup>

By International Classification of Childhood Cancer (ICCC)<sup>b</sup> Selected Group and Subgroup<sup>c</sup> and Sex and Age  
Excluding benign brain and myelodysplastic syndromes

ICCC Group & Subgroup	Ages 0-19 by Sex			Both Sexes by Age					
	Total	Male	Female	<1	1-4	5-9	10-14	15-19	0-14
All ICCC Groups Combined	78.2	76.5	80.1	72.6	80.5	76.9	77.5	78.8	77.9
I Leukemia	76.1	74.8	77.8	50.6	86.8	81.1	70.5	54.5	79.9
I(a) Lymphoid leukemia	82.1	80.2	84.4	48.3	90.7	85.0	75.9	59.1	85.0
I(b) Acute myeloid leukemia	53.0	53.9	52.0	48.3 <sup>d</sup>	62.3	56.2	55.0	43.9	56.3
II Lymphomas and reticuloendothelial neo.	87.4	86.5	88.7	55.8 <sup>d</sup>	84.8	88.6	88.9	87.6	87.1
II(a) Hodgkin lymphoma	94.6	94.9	94.2	-	100.0	94.0	94.7	94.4	94.9
II(b,c,e) Non-Hodgkin lymphoma	80.1	79.7	81.0	-	81.7	86.0	83.2	74.9	83.4
III CNS & misc intracranial & intraspinal neo.	71.3	69.9	73.1	48.1	71.0	69.1	77.8	74.4	70.7
III(a) Ependymomas and choroid plexus tumor	71.1	68.9	75.5 <sup>d</sup>	46.5 <sup>e</sup>	64.5 <sup>d</sup>	73.7 <sup>d</sup>	77.0 <sup>d</sup>	89.3 <sup>d</sup>	67.9
III(b) Astrocytoma	82.6	80.5	85.0	67.9 <sup>d</sup>	90.4	81.9	83.3	75.2	84.3
III(c) Intracranial and intraspinal embryonal tumors	65.5	66.1	64.7	32.0 <sup>d</sup>	57.2	75.9	75.7	70.9 <sup>d</sup>	64.8
III(d) Other gliomas	52.1	53.1	51.1	48.5 <sup>e</sup>	44.5 <sup>d</sup>	34.8	64.1	75.1	46.5
IV Neuroblastoma and other peripheral nervous cell tumors	68.6	68.1	69.2	90.5	61.5	46.2 <sup>d</sup>	60.0 <sup>e</sup>	64.4 <sup>e</sup>	68.7
IV(a) Neuroblastoma and ganglioneuroblastoma	68.5	67.9	69.0	90.4	61.6	44.6 <sup>d</sup>	59.8 <sup>e</sup>	-	68.7
V Retinoblastoma	97.1	96.8	97.5	99.3	95.1	100.0	-	-	97.1
VI Renal tumors	87.5	89.1	85.9	88.5	89.9	88.5	56.7 <sup>e</sup>	74.5 <sup>d</sup>	88.0
VI(a) Nephroblastoma and other nonepithelial renal tumor	88.7	91.0	86.6	88.5	90.2	87.9	65.9 <sup>e</sup>	-	88.8
VII Hepatic tumors	48.5	45.4	52.5 <sup>d</sup>	65.8 <sup>d</sup>	62.6	24.8 <sup>e</sup>	12.2 <sup>d</sup>	21.9 <sup>d</sup>	53.3
VII(a) Hepatoblastoma	60.5	55.4 <sup>d</sup>	67.0 <sup>d</sup>	67.3 <sup>d</sup>	62.8	-	-	-	60.8
VIII Malignant bone tumors	65.6	63.9	68.5	-	59.6 <sup>d</sup>	76.4	63.8	63.9	66.9
VIII(a) Osteosarcoma	66.2	64.0	69.8	-	-	72.9 <sup>d</sup>	64.9	65.3	66.9
VIII(c) Ewing tumor and related sarcomas of bone	59.8	58.8	61.5 <sup>d</sup>	-	57.0 <sup>e</sup>	83.9 <sup>d</sup>	56.9 <sup>d</sup>	52.8 <sup>d</sup>	64.6
IX Soft tissue and other extraosseous sarcomas	68.5	67.7	69.6	59.7 <sup>d</sup>	70.3	71.4	71.7	65.7	70.0
IX(a) Rhabdomyosarcoma	59.2	62.0	55.1	50.8 <sup>e</sup>	67.0	65.1	53.8 <sup>d</sup>	46.8 <sup>d</sup>	62.1
X Germ cell & trophoblastic tumors & neo. of gonads	90.1	89.4	91.4	83.6	88.3	91.2	93.0	90.5	89.6
X(a) Intracranial and intraspinal germ-cell tumor	85.6	86.1	84.4 <sup>d</sup>	-	-	95.2	89.8	81.3 <sup>d</sup>	87.6
X(c) Malignant gonadal germ cell tumor	95.5	94.5	97.6	100.0	91.3 <sup>d</sup>	97.1	100.0	94.8	97.9
XI Other malignant epithelial neo. and melanomas	89.6	84.4	92.2	-	94.2	83.7	89.9	89.8	89.0
XI(b) Thyroid carcinoma	97.9	93.9	98.8	-	-	100.0	96.0	98.2	96.8
XI(d) Malignant melanoma	94.3	94.8	93.9	-	90.3 <sup>d</sup>	90.8 <sup>d</sup>	90.8	95.3	90.7

<sup>a</sup> SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003. Rates are based on follow-up of patients into 2004.

<sup>b</sup> International Classification of Childhood Cancer is based on ICD-O-3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer. April 1, 2005: Vol 103, No. 7, pg 1457-1467.

<sup>c</sup> Classifications are shown for invasive cases only except as noted. For ICCC groups and subgroups that include *in situ* behavior, only invasive cases are shown.

<sup>d</sup> The standard error of the survival rate is between 5 and 10 percentage points.


<sup>e</sup> The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated due to fewer than 16 cases during the time period.

Neoplasms are abbreviated as neo.

Survival rates are relative rates expressed as percents.

# SEER Childhood Cancer 1996-2003 5-Year Observed Survival Rates by ICCC Group<sup>a</sup> and Race/Ethnicity Both Sexes, Under 20 Years of Age



Source: SEER 17 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey). California excluding SF/SJM/LA, Kentucky, Louisiana, and New Jersey contribute cases for diagnosis years 2000-2003. The remaining 13 SEER Areas contribute cases for the entire period 1996-2003.

International Classification of Childhood Cancer is based on ICD-0-3. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International Classification of Childhood Cancer, Third Edition. Cancer. April 1, 2005; Vol 103, No. 7, pg 1457-1467.

<sup>a</sup> Excludes Myelodysplastic syndrome (MDS) cases.

<sup>b</sup> American Indian/Alaska Native. Survival data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>c</sup> Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Survival data for Hispanics are based on NHIA and excludes cases from the Alaska Native Registry and Kentucky.